

CURRICULUM VITAE

JEFFREY K ARONSON

2 September 2016

CONTENTS

Personal details	2
Qualifications	2
Prizes and awards	2
Current appointments	2
Visiting professorships	2
Previous appointments	3
Editorial and related activities	3-4
Other activities (current and past)	
National committee memberships	4-5
Oxford University	5-6
Oxfordshire Health Authority/Oxford Radcliffe Hospitals (ORH) Trust	6
Meetings organized	6
Membership and fellowship of academic societies	6
Teaching and examining	6-7
Internal examiner	7
External examiner	7
Lectures	7-8
Research	
Recent and current research interests	8-9
Research and thesis supervision	9
Patent	9
Publications 2010-2016	
Publications with more than 100 citations	10
A Original papers	11-18
A1 Published protocols	18
B Books and edited journal issues	18-20
C Editorial reviews and commentaries—general	20-21
D Editorial commentaries—British Journal of Clinical Pharmacology	21-23
E Book chapters and reviews	23-30
F Presentations to learned societies, letters to journals, other pieces	30-35
G Medical language	35-37
H Medical humanities	37-38
I Book reviews etc	38-40
J Blogs	40-43

PERSONAL DETAILS

Date of birth: 31 August 1947
 Nationality: British
 Work address: Centre for Evidence Based Medicine (cebm.cet)
 Nuffield Department of Primary Care Health Sciences
 University of Oxford, New Radcliffe House, Radcliffe
 Observatory Quarter, Woodstock Road, Oxford OX2 6GG
 GMC registration number: 1319800
 E-mail: jeffrey.aronson@phc.ox.ac.uk
 Web site: <https://www.phc.ox.ac.uk/team/researchers/jeffrey-aronson>
 Twitter: @JKAronson

QUALIFICATIONS

MB ChB Glasgow University, 1970
 MRCP (UK) 1973
 DPhil Oxford University (Corpus Christi College), 1977 [Studies on
 the clinical pharmacology of cardiac glycosides]
 MA Oxford University, 1984
 FRCP Royal College of Physicians, 1985
 FBPhS British Pharmacological Society, 2004
 HonFFPM Faculty of Pharmaceutical Medicine of the RCP, 2007
 HonFBPhS British Pharmacological Society, 2014

PRIZES AND AWARDS

University Distinction in Materia Medica (Glasgow University), 1967
 First prize (shared with JA Muir Gray), annual Scottish Chest and Heart Association
 competition, 1968
 Nuffield Bursary, Middlesex Hospital, August–December 1969
 Paul Martini Prize, for the development of methods for evaluation in the fields of clinical
 pharmacology and therapeutics, 1980
 Australasian Visitor, British Pharmacological Society, 1985
 Smith, Kline and French Foundation Travelling Prize for Research in Clinical
 Pharmacology (awarded by the British Pharmacological Society), 1988
 Honorary Fellowship of the Faculty of Pharmaceutical Medicine, 2007
 Honorary Fellowship of the British Pharmacological Society, 2014

CURRENT APPOINTMENTS

Clinical Pharmacologist, Centre for Evidence Based Medicine, Nuffield Department of
 Primary Care Health Sciences, University of Oxford
 Honorary Consultant Physician, Oxford University Hospitals NHS Trust

VISITING PROFESSORSHIPS

December 1991 University of Cear, Brazil
 November 1997 University of Kentucky, Louisville
 November 2000 University of Colombo, Sri Lanka
 December 2015 Seoul National University Hospital, S Korea

PREVIOUS APPOINTMENTS

August 1970–January 1971	Junior Medical House Officer, Southern General Hospital, Glasgow
February 1971–July 1971	Junior Surgical House Officer, Victoria Infirmary, Glasgow
August 1971–April 1973	Senior Medical House Officer, Stobhill Hospital, Glasgow
May 1973–August 1973	Medical Registrar, Stobhill Hospital, Glasgow
September 1973–October 1980	Member of Scientific Staff, MRC Unit and University Department of Clinical Pharmacology, Radcliffe Infirmary, Oxford
September 1973–August 1977	Honorary Registrar in Clinical Pharmacology, Oxfordshire Health Authority
September 1977–October 1980	Honorary Senior Registrar in Clinical Pharmacology, Oxfordshire Health Authority
August 1979–October 1980	Senior Registrar in General Medicine, Oxfordshire Health Authority
November 1980–October 1984	Wellcome Lecturer and Consultant in Clinical Pharmacology, University of Oxford
November 1984–December 1993	Reader and Consultant in Clinical Pharmacology (Wellcome Lecturer), University of Oxford
January 1994–September 2014	Reader in Clinical Pharmacology, University of Oxford, and Honorary Consultant Physician Oxford University Hospitals Trust

EDITORIAL AND RELATED ACTIVITIES

BMJ

Guest Editor, BMJ special issue: “Balancing benefits and harms in health care”, 3 July 2004

British Journal of Clinical Pharmacology

Member, Editorial Board, 1986–91, 2000–2

Editor-in-Chief, 2002–7

Editor, special issues: “Citation Classics in the British Journal of Clinical Pharmacology, 1974–2003”, December 2004; “Clinical Pharmacology: Past, Present, and Future”, June 2006; “Adverse Drug Reactions”, February 2007; “Medication Errors”, June 2009; “An Agenda for UK Clinical Pharmacology”, June 2012

European Journal of Clinical Pharmacology

Managing Editor, 1985–93; Reviews Editor, 1994–2002

Prescribers' Journal

Chairman of the Committee of Management [Editorial Board], 1994–6 (Vice-Chairman, 1992–4; Member 1990–6)

Member of the Editorial Advisory Panel, 1996–2000

British National Formularies

Member, Steering Group for the British National Formulary for Children, 2003–4; Paediatric Formulary Committee 2004–12

Member, Joint Formulary Committee of the British National Formulary, 2006–2012

Member, Advisory Board of the British National Formularies, 2012–

Royal College of Physicians

Guest Editor, Clinical Medicine (RCP) issue on CME in Clinical Pharmacology, 2009
 Member, Advisory Board (RCP representative), National Patient Safety Agency, 2009–2010

Member, Advisory Board (RCP representative), NHS Evidence, 2010–12

Edited textbooks

Co-editor, Meyler's Side Effects of Drugs, 14th edition, 2000

Editor, Meyler's Side Effects of Drugs—The International Encyclopedia of Adverse Drug Reactions and Interactions, 15th edition (six-volume encyclopedia and web version), 2006

Editor, Meyler's Side Effects of Drugs—The International Encyclopedia of Adverse Drug Reactions and Interactions, 16th edition (seven-volume encyclopedia and web version), 2015

Editor, Side Effects of Drugs Annuals, Volumes 15–35, 1991–2014

Glasziou P, Irwig L, Aronson JK, editors. Evidence-based Medical Monitoring: From Principles to Practice. Oxford: Blackwell Publishing/BMJ Books, 2008.

Talbot J, Aronson JK, editors. Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice. 6th edition. Oxford: Wiley-Blackwell, 2011

Others

Member of the Board of Management, Reuters Journalists' Fellowship Programme, Oxford, 1992–2005

Chairman of the British Pharmacopoeia Commission's Expert Advisory Group on Nomenclature, 2006– (member 1995–2006)

Member, Advisory Editorial Board, Oxford Today (editor Georgina Ferry), 2002–7

Member, Board of 'Prescribe', Department of Health, e-Learning for Health, 2009–2010

Member, NIHR (National Institute for Health Research) Journals Library Board, 2012–

Member of the Editorial Boards of:

Clinical Science, 1984–8

Archives Internationales de Pharmacodynamie et de Thérapie, 1976–96

The Wellness Letter, 1992–3

Adverse Drug Reactions Bulletin, 1996–

Cases Journal, 2008–10

Drug Safety Case Reports 2016–

Regular reviewer for numerous bioscience journals, including the BMJ, The Lancet, Drug Safety, BMC Journals, PLoS Medicine, PLoS One

Consultant on medical and pharmacological words, Collins English Dictionary, editions 6–11

OTHER ACTIVITIES (current and past)

National committees and learned societies

President Emeritus, British Pharmacological Society 2010– (President 2008–9; President-elect 2006–7); Trustee, Member of Council, and Member of the Executive Committee, 2002–9; Honorary Fellow 2014–

Member, Advisory Board of the British National Formularies, 2012–

Member, NIHR (National Institute for Health Research) Journals Library Board, 2012–

Member, Advisory Board (RCP representative), NHS Evidence, 2010–12

Member, Task and Finish Working Group of the HE/Industry Forum of the Office for Life Sciences, 2009–10

Member, Advisory Board (RCP representative), National Patient Safety Agency, 2009–2010
Member, Board of 'Prescribe', Department of Health, e-Learning for Health, 2009–2010
Member of Technology Appraisal Committee, NICE, 2006–
Member, Joint Formulary Committee of the British National Formulary, 2006–2012
Chairman of the British Pharmacopoeia Commission's Expert Advisory Group on Nomenclature, 2006– (member 1995–2006)
Member of the Health Technology Assessment's Commissioning Board, 2003–7
Member, Steering Group for the British National Formulary for Children, 2003–4; Paediatric Formulary Committee 2004–12
Vice Chairman, Medicines Commission, 2002–5 (Member 2001–5)
Chairman, Joint (CSM and Medicines Commission) Working Group on the Prescribing, Supply and Administration of Medicines (2002–4)
Member of the Wellcome Trust's History of Medicine Grants and Units Panel [from 1998 Grants Panel], 1993–2000 (Deputy Chairman 1996–2000); Chairman, quinquennial review of the London History of Medicine Unit, 2000
Member of the Wellcome Trust's Medicine, Society, and History Committee (previously History of Medicine Committee), 1993–2000
Member of the Medical Research Council's Committee on Therapeutic Trials in AIDS and chairman of its Subgroup on New Therapeutic Agents, 1987–93

Oxford University

Associate Member, Department of Pharmacology, 2009–
Head of Department, University Department of Clinical Pharmacology, 1990–1, 2000–1
Fellow of Green College, 1984–2008 (Tutor for Admissions, 1986–8; Senior Tutor 1994–7)
Fellow of Green-Templeton College, 2008–2014; Emeritus Fellow, 2014–
Visitor of the Museum for the History of Science, 2003–7
Member of the Division of Medical Sciences, 2000–14
Member of the Management Committee of the Wellcome Unit for the History of Medicine, 2000–5
Member of the Committee for the History of Science, Medicine, and Technology, 2000–5
Honorary Associate Member, Wellcome Unit for the History of Medicine, 1998–
Member of the Board of the Faculty of Clinical Medicine 1997–2000
Curator of the Bodleian Library, 1995–9
Clinical representative on the core curriculum committee (preclinical), 1995–8, and its physiology and pharmacology subcommittee, 1998–2008
University representative on the liaison committee of the Oxford University SmithKline Beecham Centre for Applied Neuropsychobiology, 1990–9
Oxford University Assessor, 1989–90
Member of the Management Board for Library Services to the Faculty Board of Clinical Medicine, 1994–7
Member of the Libraries' Board, 1994–7
Member of the Applications Committee of the Faculty Board of Clinical Medicine, 1993–5
Member of the International Committee, 1992–9
Member of the Board of Management of the Astor Fund, 1992–2001
Member of the Committee for the Admission of Medical Students to the Oxford Medical School, 1985–8

Oxfordshire Health Authority/Oxford Radcliffe [now Oxford University] Hospitals Trust (ORH/OUH Trust)

Regional SAC representative for Clinical Pharmacology and Therapeutics, 2000–
Deputy Chairman, Drug and Therapeutics Committee (Medicines Advisory Committee),
ORH/OUH Trust, 1980–2001; Member, 2001–
Member of the ORH Trust's Technology Advisory Group, 2002–6
University representative on the Executive Board of the ORH Trust, 2001–2
Member of the ORH Trust's Discretionary Awards Committee, 1998–2001
Member of the Clinical Research Subcommittee of the Anglia and Oxford Regional Health
Authority, 1995–9
Member of the Oxfordshire Health Authority's Medical Advisory Group, 1993–5
On-take physician, ORH Trust, 1992–2008
Member of the Central Oxford Research Ethics Committee (now OxREC), 1982–6
(Chairman 1984–6)

Meetings organized

Co-founder (with JC Ellory): Oxford Ion Transport Club (organizer 1989–92)
Organizer: Penicillin 50 Symposium, Oxford 1991
Organizer (with Giampaolo Velo): Medication Errors, Erice, June 2008
Organizer: James Black Meeting—Planning a 5-year agenda for UK clinical pharmacology,
Oxford 2011
Organizer (with Giampaolo Velo): The Future of European Clinical Pharmacology and
Therapeutics, Erice, June 2012
Organizer, Oxford meetings of the Clinical Pharmacology Colloquium
Prescribing Masterclass, Oxford September 2014
Organizer (with Giampaolo Velo and Pietro Minuz): Medication Errors, Erice, May 2016

MEMBERSHIP & FELLOWSHIP OF ACADEMIC SOCIETIES

Honorary Fellow of the British Pharmacological Society, 2014– (Fellow 2004–14;
Member 1977–2003), Member of the Committee of its Clinical Section, 1985–9;
Trustee and Member of Council, 2002–9; President-elect, 2006–7; President 2008–9,
President Emeritus 2010–
Member of the Medical Research Society, 1984–
Fellow of the Royal College of Physicians, 1985–
Member of the Association of Physicians of Great Britain and Ireland, 1988– (Senior
Member 2007–)
Member of the Medical Society of London, 2002–
Honorary Fellow of the Faculty of Pharmaceutical Medicine, 2007–
Honorary Fellow of the British Pharmacological Society, 2014–

TEACHING AND EXAMINING

Undergraduate and postgraduate teaching activities include numerous lectures on drug
therapy to clinical students, regular bedside/seminar teaching on drug therapy and
clinical medicine to clinical students, special study modules, and seminars and lectures
on drug therapy for GPs, specialists, doctors in training, nurses, and pharmacists

Internal examiner

First BM examinations 1994–6 (Chairman of Examiners, 1995–6); 2000–2
Frequent examiner of DM, DPhil, and MSc theses

External examiner/adviser

Programme and Module External Examiner, Pan-European MSc in Pharmacovigilance and Pharmacoepidemiology (Universitat Autònoma de Barcelona, Université Bordeaux Segalen, University of Hertfordshire, Erasmus Universiteit Rotterdam, Universiteit Utrecht, Università degli Studi di Verona), 2011–
Appointments panel, Chair of Clinical Pharmacology, Lausanne, 2011
Clinical Pharmacology (MSc), Aberdeen, 2004–6
Pharmacology & Therapeutics (BMedSci), Sheffield, 1996
Clinical Pharmacology (MBChB), Sheffield, 1994–6
Pharmacology (MBBS), Cardiff, 1990–3
Pharmacology and Clinical Pharmacology & Therapeutics, London University (BSc and MBBS, various medical schools), 1983–92; 1998–2000
MD/PhD theses: Liverpool, 1987; Cambridge, 1990; Hong Kong, 1991; Leicester, 1993; Otago, NZ, 1995; QMUL, London, 2009; Birmingham 2013; York 2013; Lausanne 2013–15

LECTURES

Numerous invited national and international lectures, including the following named and plenary lectures:

SKF Prize Lecture (British Pharmacological Society), 1989: Blood and ions

Lettsomian Lecture (Medical Society of London), 2003: John Coakley Lettsom and the introduction of digitalis into clinical practice at the end of the eighteenth century. *Trans Med Soc Lond* 2002-3; 119: 77-85. [PMID: 17184033]

Lord Cohen Lecture, Liverpool, 2006: The demedicalization of prescribing

John Ash Lecture, Birmingham, 2006: “A direct contrary road”—medical disputation in John Ash’s Birmingham

FitzPatrick Lecture, Royal College of Physicians, London, 2007: Clinical pharmacology: a suitable case for treatment. https://admin.emea.acrobat.com/_a45839050/p74648562/

ASCEPT (Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists), Adelaide, 2007: Plenary lectures: Classifying adverse drug reactions—from dichotomy to polytomy; Lessons from Vioxx: a regulatory approach to problematic drugs—joining the DoTS

Gideon de Laune Lecture, Society of Apothecaries, London, 2008: “PoM to P” Selling medicines to patients. *BMJ* 2009; 339: b5415. [PMID: 20008435]

EUFEPS (European Federation of Pharmaceutical Sciences), Verona, 2008: “The law of life” How do clinicians perceive and act on variability in drug response?

WHO Adverse Drug Reactions Monitoring Centre, Uppsala, 2008: “Aristotle's prior knowledge” The general approach to definition and its relevance to signal detection in drug safety

ESPACOMP (European Society for Patient Adherence, Compliance, and Persistence), Bangor, 2009: Adding PEP to prescribing—the definitive method

President’s Lecture (British Pharmacological Society), London, 2009: Clinical Pharmacology—Past, Present, and (YES) Future

- WorldPharma, Copenhagen 2010. Opening plenary lecture. “Found in translation” Human pharmacology and applied pharmacology come of age. <http://www.bps.ac.uk/SpringboardWebApp/userfiles/bps/file/Meetings/WPJAransonFoundInTranslationLecture.pdf>
- Nobel Symposium, Karolinska Institute, 2010. Sex, gender, and pharmacology. The UK and European experience. <http://www.informationsteknikstreaming.se/sll/101019>
- International Society of Pharmacovigilance, Istanbul, 2011. “Better than cure”: Assessing the preventability of adverse drug reactions
- International Society of Pharmacovigilance, Cancun, 2012. The Law of Mass Action: Relevance to Pharmacovigilance
- European Medicines Agency, Medication Errors Workshop, 2013. Do we have a common understanding of medication errors? http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/events/2012/10/event_detail_000666.jsp&mid=WC0b01ac058004d5c3
- Faculty of Occupational Medicine. Fitness for Work Conference, 2013. “Worse than a crime” Medication errors”
- EACPT (European Association of Clinical Pharmacology and Therapeutics), Edinburgh 2013. Translation and the future of clinical pharmacology
- EACPT (European Association of Clinical Pharmacology and Therapeutics), Geneva 2013. Monitoring drug therapy—TDM: Te deum or tedium?
- MHRA (Medicines and Healthcare products Regulatory Agency). Yellow Card 50th Anniversary Strategic Forum, London 2014: What do we NOT do? What could we do better?
- British Association for Psychopharmacology, February 2015, London. Monitoring lithium therapy
- ASCPT (American Society of Clinical Pharmacology and Therapeutics), March 2015, New Orleans. The future of clinical pharmacology
- KSCPT (Korean Society of Clinical Pharmacology and Therapeutics), December 2015, Seoul. A VOICE for clinical pharmacology
- Dansk Selskab for Klinisk Farmakologi (Danish Society of Clinical Pharmacology), April 2016, Copenhagen. Translational research and a VOICE for clinical pharmacology

RESEARCH

Recent and current research interests

- Methods of classifying, detecting, and reporting adverse drug reactions, including systematic reviews, meta-analyses, and the use of anecdotal reports (including collaborations with Professor RE Ferner, Birmingham, Dr M Hauben, New York, and others)
- Spurious/falsely-labelled/falsified/counterfeit (SFFC) medicines
- Innovation in drug therapy (collaborations with Professor RE Ferner, University of Birmingham, and Professor DA Hughes, University of Bangor)
- Monitoring therapy in chronic disease (collaborations with Professor Paul Glasziou, Brisbane, Professor Thierry Buclin, Lausanne, Rafael Perera, Oxford, and others)
- Pharmacological and therapeutic effects of drugs in diabetes mellitus (collaborations with various members of the Nuffield Department of Primary Care Health Sciences, Oxford)

Systematic reviews of pharmacokinetics, pharmacodynamics, and pharmacokinetic–dynamic modelling (collaboration with Dr Richard Stevens, Nuffield Department of Primary Care Health Sciences, Oxford)

The philosophy of evidence-based medicine (collaborations with Dr Jeremy Howick Department of Primary Care Health Sciences, Oxford, and others)

Simple and cheap methods of medical management of toxicological problems in a developing country (collaboration with Professor HA de Silva and colleagues, University of Colombo, Sri Lanka)

Developing a toolkit for patient safety in general practice (collaboration with Professor Tony Avery, Nottingham, and others)

The causes and consequences of postmarketing drug withdrawals (licence revocations) (collaboration with Professor Carl Heneghan)

Medication errors (various collaborations)

Research and thesis supervision

Numerous MD, DPhil, and MSc students, 1977–

Patent

Aronson JK, De Silva HA, Grahame-Smith DG. US Patent No. 6,087,118. Method for diagnosing Alzheimer's disease

PUBLICATIONS

Publications with more than 100 citations (Google Scholar; h index 43):

- 1629: Edwards IR, Aronson JK. Adverse drug reactions—definitions, classification, diagnosis, management, surveillance. *Lancet* 2000; 356: 1255-60. [PMID: 11072960]
- 287: Grahame-Smith DG, Aronson JK. *The Oxford Textbook of Clinical Pharmacology and Drug Therapy*. Second edition. Oxford: Oxford University Press, 1992.
- 277: Barkun JS, Aronson JK, Feldman LS, Maddern GJ, Strasberg SM; Balliol Collaboration, Altman DG, Barkun JS, Blazeby JM, Boutron IC, Campbell WB, Clavien PA, Cook JA, Ergina PL, Flum DR, Glasziou P, Marshall JC, McCulloch P, Nicholl J, Reeves BC, Seiler CM, Meakins JL, Ashby D, Black N, Bunker J, Burton M, Campbell M, Chalkidou K, Chalmers I, de Leval M, Deeks J, Grant A, Gray M, Greenhalgh R, Jenicek M, Kehoe S, Lilford R, Littlejohns P, Loke Y, Madhock R, McPherson K, Rothwell P, Summerskill B, Taggart D, Tekkis P, Thompson M, Treasure T, Trohler U, Vandenbroucke J. Surgical Innovation and Evaluation. 1. Evaluation and stages of surgical innovations. *Lancet* 2009; 374(9695): 1089-96. [PMID: 19782874]
- 227: Vrijens B, De Geest S, Hughes D, Kardas P, Demonceau J, Ruppert T, Dobbels F, Fargher E, Morrison V, Lewek P, Matyjaszczyk M, Mshelia C, Clyne W, Aronson JK, Urquhart J; ABC project team. A new taxonomy for describing and defining adherence to medications. *Br J Clin Pharmacol* 2012; 73(5): 691-705. [PMID: 22486599]
- 199: Aronson JK, Ferner RE. Joining the DoTS. New approach to classifying adverse drug reactions. *BMJ* 2003; 327: 1222-5. [PMID: 14630763]
- 179: Aronson JK, Hauben M. Anecdotes that provide definitive evidence. *BMJ* 2006; 332(7581): 1267-9. [PMID: 17170419]
- 177: Aronson JK, editor. *Meyler's Side Effects of Drugs. An Encyclopedia of Adverse Reactions and Interactions*. 16th edition. Amsterdam: Elsevier, 2015
- 176: Smith CC, Bennett PM, Pearce HM, Harrison PI, Reynolds DJM, Aronson JK, Grahame-Smith DG. Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. *Br J Clin Pharmacol* 1996; 42(4): 423-9. [PMID: 8904613]
- 172: Aronson JK. Anecdotes as evidence. We need guidelines for reporting anecdotes of suspected adverse drug reactions. *BMJ* 2003; 326(7403): 1346. [PMID: 12816800]
- 169: Aronson JK. A prescription for better prescribing. *Br J Clin Pharmacol* 2006; 61(5): 487-91. [PMID: 16669839]
- 168: Aronson JK. Medication errors: definitions and classification. *Br J Clin Pharmacol* 2009; 67(6): 599-604. [PMID: 19594526]
- 166: Dukes MNG, Aronson JK, editors. *Meyler's Side Effects of Drugs. An Encyclopedia of Adverse Reactions and Interactions*. 14th edition. Amsterdam: Elsevier, 2000
- 155: Aronson JK, Ferner RE. Clarification of terminology in drug safety. *Drug Saf* 2005; 28(10): 851-70. [PMID: 16180936]
- 152: Ferner RE, Aronson JK. Clarification of terminology in medication errors: definitions and classification. *Drug Saf* 2006; 29(11): 1011-22. [PMID: 17061907]
- 143: Aronson JK. Medication errors: what they are, how they happen, and how to avoid them. *QJM* 2009; 102(8): 513-21. [PMID: 19458202]
- 140: Aronson JK. Compliance, concordance, adherence. *Br J Clin Pharmacol* 2007; 63(4): 383-4. [PMID: 17378797]
- 132: Willoughby PB, Aronson JK, Agback H, Bodin NO, Truelove SC. Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. *Gut* 1982; 23(12): 1081-7. [PMID: 7173720]
- 114: Azad Khan AK, Truelove SC, Aronson JK. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. *Br J Clin Pharmacol* 1982; 13(4): 523-8. [PMID: 6121576]
- 111: Derry S, Loke YK, Aronson JK. Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. *BMC Med Res Methodol* 2001; 1: 7. <http://www.biomedcentral.com/1471-2288/1/7/> Epub 2001 Sep 3. [PMID: 11591220]
- 108: Loke YK, Price D, Derry S, Aronson JK. Case reports of suspected adverse drug reactions—systematic literature survey of follow-up. *BMJ* 2006; 332(7537): 335-9. Epub 2006 Jan 18. [PMID: 16421149]
- 108: de Silva HA, Fonseka MMD, Pathmeswaran A, Alahakoon DGS, Ratnatilake GA, Gunatilake SB, Ranasinha CD, Laloo DG, Aronson JK, de Silva HJ. Multiple-dose activated charcoal for treatment of yellow oleander poisoning: a single-blind, randomized, placebo-controlled trial. *Lancet* 2003; 361(9373): 1935-8. [PMID: 12801736]

PUBLICATIONS 1975–2016

A Original papers

1. Aronson JK, Grahame-Smith DG. Digoxin therapy: textbooks, theory and practice. *Br J Clin Pharmacol* 1976; 3(4): 639-48. [Correction in: *Br J Clin Pharmacol* 1976 October; 3(5): i3.] [PMID:22216507]
2. Aronson JK, Grahame-Smith DG. Altered distribution of digoxin in renal failure—a cause of digoxin toxicity? *Br J Clin Pharmacol* 1976; 3(6): 1045-51. [PMID:22216528]
3. Aronson JK, Grahame-Smith DG, Hallis KF, Hibble AG, Wigley FM. Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response. *Br J Clin Pharmacol* 1977; 4(2): 213-21. [PMID: 861136]
4. Aronson JK, Grahame-Smith DG. Monitoring digoxin therapy: II. Determinants of the apparent volume of distribution. *Br J Clin Pharmacol* 1977; 4(2): 223-7. [PMID: 861137]
5. Aronson JK. Monitoring digoxin therapy: III. How useful are the nomograms? *Br J Clin Pharmacol* 1978; 5(1): 55-64. [PMID: 619935]
6. Aronson JK, Grahame-Smith DG, Wigley FM. Monitoring digoxin therapy: the use of plasma digoxin concentration measurements in the diagnosis of digoxin toxicity. *QJM* 1978; 47(186): 111-12. [PMID: 684152]
7. Williams P, Aronson JK, Sleight P. Is a slow pulse rate a reliable sign of digitalis toxicity? *Lancet* 1978; 2(8104-5): 1340-2. [PMID: 82842]
8. Youdim MBH, Aronson JK, Blau K, Green AR, Grahame-Smith DG. Tranylcpromine ('Parnate') overdose: measurement of tranylcpromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma. *Psychol Med* 1979; 9(2): 377-82. [PMID: 472083]
9. Ford AR, Aronson JK, Grahame-Smith DG, Rose JA. The characteristics of the binding of 12- α -³H-digoxin to the membranes of intact human erythrocytes. *Br J Clin Pharmacol* 1979; 8(2): 115-24. [PMID: 486288]
10. Ford AR, Aronson JK, Grahame-Smith DG, Carver JG. Changes in cardiac glycoside receptor sites, ⁸⁶rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients receiving digoxin during the early phases of treatment of cardiac failure in regular rhythm and of atrial fibrillation. *Br J Clin Pharmacol* 1979; 8(2): 125-34. [PMID: 486289]
11. Ford AR, Aronson JK, Grahame-Smith DG, Carver JG. The acute changes seen in cardiac glycoside receptor sites, ⁸⁶rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients during the early phases of digoxin therapy are not found during chronic therapy: pharmacological and therapeutic implications for chronic digoxin therapy. *Br J Clin Pharmacol* 1979; 8(2): 135-42. [PMID: 486290]
12. Aronson JK, Ford AR. The use of colour vision measurement in the diagnosis of digoxin toxicity. *QJM* 1980; 49(195): 273-82. [PMID: 6970370]
13. Green AR, Aronson JK, Curzon G, Woods HF. Metabolism of an oral tryptophan load. I: Effects of dose and pretreatment with tryptophan. *Br J Clin Pharmacol* 1980; 10(6): 603-10. [PMID: 6162471]
14. Green AR, Aronson JK, Curzon G, Woods HF. Metabolism of an oral tryptophan load. II: Effect of pretreatment with the putative pyrrolase inhibitors nicotinamide or allopurinol. *Br J Clin Pharmacol* 1980; 10(6): 611-15. [PMID: 6451235]
15. Green AR, Aronson JK. Metabolism of an oral tryptophan load. III: Effect of a pyridoxine supplement. *Br J Clin Pharmacol* 1980; 10(6): 617-19. [PMID: 7470373]
16. Aronson JK, Geaney DP, Grahame-Smith DG, Carver JG, Hallis KF. Lack of effect of phenytoin on functions related to Na⁺,K⁺-ATPase activity in the intact erythrocytes of epileptic patients. *Br J Clin Pharmacol* 1981; 12(1): 79-81. [PMID: 6264938]
17. Azad Khan AK, Truelove SC, Aronson JK. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. *Br J Clin Pharmacol* 1982; 13(4): 523-8. [PMID: 6121576]
18. Zannad F, Graham CW, Aronson JK. The effect of digoxin and dopamine on the oxygen consumption, lactate production and haemodynamic performance of an isolated, perfused, working guinea-pig heart. *Eur J Pharmacol* 1982; 81(2): 263-71. [PMID: 7117376]
19. Geaney DP, Carver JG, Aronson JK, Warlow C. Interaction of phenytoin with azapropazone. *Br Med J (Clin Res Ed)* 1982; 284(6326): 1373. [PMID: 6803981]
20. Willoughby PB, Aronson JK, Agback H, Bodin NO, Truelove SC. Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. *Gut* 1982; 23(12): 1081-7. [PMID: 7173720]
21. Geaney DP, Carver JG, Davies CL, Aronson JK. Pharmacokinetic investigation of the interaction of azapropazone with phenytoin. *Br J Clin Pharmacol* 1983; 15(6): 727-34. [PMID: 6871071]

22. Boon NA, Rose JA, Hallis KF, Jones JV, Manley BS, Aronson JK. Evidence that cation transport is reduced in one-kidney one clip hypertension. *J Hypertens Suppl* 1983; 1(2): 129-31
23. Boon NA, Aronson JK, Hallis KF, White NJ, Raine AEG, Grahame-Smith DG. A method for the study of cation transport in vivo: effects of digoxin administration and of chronic renal failure on the disposition of an oral load of rubidium chloride. *Clin Sci (Lond)* 1984; 66(5): 569-74. [PMID: 6705481]
24. Aronson JK, Moore MP, Redman CWG, Harper C. Erythrocytic cation transport receptor numbers and activity in pregnancies complicated by essential hypertension and pre-eclampsia. *Br Med J (Clin Res Ed)* 1984; 288(6427): 1332-4. [PMID: 6424846]
25. Boon NA, Oh VMS, Taylor EA, Johansen T, Aronson JK, Grahame-Smith DG. Measurement of specific [³H]-ouabain binding to different types of human leucocytes. *Br J Clin Pharmacol* 1984; 18(2): 153-61. [PMID: 6487454]
26. Boon NA, Aronson JK, Hallis KF, Raine AEG, Grahame-Smith DG. An in vivo study of cation transport in essential hypertension. *J Hypertens Suppl* 1984; 2(3): S457-9. [PMID: 6100748]
27. Boon NA, Harper C, Aronson JK, Grahame-Smith DG. Cation transport functions in vitro in patients with untreated essential hypertension: a comparison of erythrocytes and leucocytes. *Clin Sci (Lond)* 1985; 68(5): 511-15. [PMID: 3979014]
28. Hallis KF, Boon NA, Perkins CM, Aronson JK, Grahame-Smith DG. A sensitive high-temperature electrothermal atomic absorption analysis of Rb⁺ in erythrocytes and plasma of normal and hypertensive persons. *Clin Chem* 1985; 31(2): 274-6. [PMID: 3967362]
29. Green AR, Aronson JK, Cowen PJ. The pharmacokinetics of L-tryptophan following its intravenous and oral administration. *Br J Clin Pharmacol* 1985; 20(4): 317-21. [PMID: 4074600]
30. Boon NA, Aronson JK, Hallis KF, Grahame-Smith DG. Cation transport abnormalities in vivo in untreated essential hypertension. *Clin Sci (Lond)* 1986; 70(6): 611-16. [PMID: 3709067]
31. Boon NA, Pugh, SE, Hallis KF, Aronson JK, Grahame-Smith, DG. In vivo cation transport during short-term and long-term digoxin therapy. *Br J Clin Pharmacol* 1986; 22(1): 27-30. [PMID: 3741723]
32. Rapeport WG, Aronson JK, Grahame-Smith DG, Harper C. The effects of serum, lithium, ethacrynic acid, and a low external concentration of potassium on specific [³H]-ouabain binding to human lymphocytes after incubation for 3 days. *Br J Clin Pharmacol* 1986; 22(3): 275-9. [PMID: 3768239]
33. Oh VMS, Taylor EA, Ding JL, Boon NA, Aronson JK, Grahame-Smith DG. Enhancement of specific ouabain binding and ouabain-sensitive ⁸⁶rubidium uptake in intact human lymphocytes by a dialysable factor in human and fetal calf sera. *Clin Sci (Lond)* 1987; 72(1): 71-9. [PMID: 2879663]
34. Wood AJ, Viswalingam A, Glue P, Aronson JK, Grahame-Smith DG. Measurement of cation transport in vivo in healthy volunteers after the oral administration of lithium carbonate. *Clin Sci (Lond)* 1989; 76(4): 397-402. [PMID: 2540932]
35. Wood AJ, Aronson JK, Bunch C, Grahame-Smith DG. A study of the transport of lithium across the erythrocyte membrane in vivo and of the effects of the ion transport inhibitors digoxin and dipyrindamole. *Br J Clin Pharmacol* 1989; 27(6): 749-56 [PMID: 2757891]
36. Pugh SE, White NJ, Aronson JK, Grahame-Smith DG, Bloomfield JG. Clinical, haemodynamic, and pharmacological effects of withdrawal and reintroduction of digoxin in patients with heart failure in sinus rhythm after long-term treatment. *Br Heart J* 1989; 61(6): 529-39. [PMID: 2503017]
37. Wood AJ, Elphick M, Aronson JK, Grahame-Smith DG. The measurement of transmembrane cation transport in vivo in acute manic illness. *Br J Psychiatry* 1989; 155(4): 501-4. [PMID: 2558772]
38. Wood AJ, Elphick M, Aronson JK, Grahame-Smith DG. The effect of lithium on cation transport measured in vivo in patients suffering from bipolar affective illness. *Br J Psychiatry* 1989; 155(4): 504-10. [PMID: 2558773]
39. Syme PD, Dixon RM, Allis JL, Aronson JK, Grahame-Smith DG, Radda GK. A non-invasive method of measuring concentrations of rubidium in rat skeletal muscle in vivo by ⁸⁷Rb nuclear magnetic resonance spectroscopy: implications for the measurement of cation transport activity in vivo. *Clin Sci (Lond)* 1990; 78(3): 303-9. [PMID: 2156650]
40. Wood AJ, Brearley CJ, Aronson JK, Grahame-Smith DG. The effect of oral salbutamol on cation transport measured in vivo in healthy volunteers. *Br J Clin Pharmacol* 1990; 30(3): 383-90. [PMID: 2171617]
41. Kennedy DG, Aronson JK, Bloomfield JG, Grahame-Smith DG. The effects of a low extracellular concentration of potassium on the activity and numbers of Na⁺/K⁺ pumps in an EB-virus transformed human lymphocyte cell line. *Biochimica et Biophysica Acta (BBA)-Biomembranes* 1990; 1027(3): 218-24. [PMID: 1975752]

42. Syme PD, Arnolda L, Green Y, Aronson JK, Grahame-Smith DG, Radda GK. Evidence for increased in vivo Na^+/H^+ antiport activity and an altered skeletal muscle contractile response in the spontaneously hypertensive rat. *J Hypertens* 1990; 8(11): 1027-36. [PMID: 1963185]
43. Syme PD, Dixon RM, Aronson JK, Grahame-Smith DG, Radda GK. Evidence for increased in vivo sodium-potassium pump activity and potassium efflux in skeletal muscle of spontaneously hypertensive rats. *J Hypertens* 1990; 8(12): 1161-6. [PMID: 1962807]
44. Moraes MEA, Aronson JK, Grahame-Smith DG. Intravenous strontium gluconate as a kinetic marker for calcium in healthy volunteers. *Br J Clin Pharmacol* 1991; 31(4): 423-7. [PMID: 2049251]
45. Wood AJ, Smith CE, Clarke EE, Cowen PJ, Aronson JK, Grahame-Smith DG. Altered in vitro adaptive responses of lymphocyte Na^+, K^+ -ATPase in patients with manic depressive psychosis. *J Affect Disord* 1991; 21(3): 199-206. [PMID: 1648581]
46. Davies JE, Ng LL, Ameen M, Syme PD, Aronson JK. Evidence for altered Na^+/H^+ antiport activity in cultured skeletal muscle cells and vascular smooth muscle cells from the spontaneously hypertensive rat. *Clin Sci (Lond)* 1991; 80(5): 509-16. [PMID: 1851693]
47. Jenkins RJ, Aronson JK, Brearley CJ. Increases in Na/K pump numbers in isolated human lymphocytes exposed to lithium in vitro. Reversal by myo-inositol and by inhibitors of protein kinase C and the Na/H antiport. *Biochim Biophys Acta (BBA)—Molecular Cell Research* 1991; 1092(2): 138-44. [PMID: 1850301]
48. Syme PD, Brunotte F, Green Y, Aronson JK, Radda GK. The effect of β_2 -adrenoceptor stimulation and blockade of L-type calcium channels on in vivo Na^+/H^+ antiporter activity in rat skeletal muscle. *Biochim Biophys Acta (BBA)—Molecular Cell Research* 1991; 1093(2-3): 234-40. [PMID: 1650580]
49. Moraes MEA, Aronson JK, Grahame-Smith DG. The effect of nifedipine on the disposition of strontium gluconate used as a kinetic marker for calcium in healthy volunteers. *Br J Clin Pharmacol* 1991; 32(4): 441-5. [PMID: 1958437]
50. Syme PD, Aronson JK, Thompson CH, Williams EM, Green Y, Radda GK. Na^+/H^+ and $\text{HCO}_3^-/\text{Cl}^-$ exchange in the control of intracellular pH in vivo in the spontaneously hypertensive rat. *Clin Sci (Lond)* 1991; 81(6): 743-50. [PMID: 1662580]
51. Ameen M, Bloomfield JG, Aronson JK. Reversal of the effects of a low extracellular potassium concentration on the number and activity of Na^+/K^+ pumps in an Epstein-Barr virus-transformed human lymphocyte cell line. *Biochem Pharmacol* 1992; 43(3): 489-96. [PMID: 1311581]
52. Antia IJ, Dorkins CE, Wood AJ, Aronson JK. Increase in Na^+/K^+ pump numbers in vivo in healthy volunteers taking oral lithium carbonate and further upregulation in response to lithium in vitro. *Br J Clin Pharmacol* 1992; 34(6): 535-40. [PMID: 1337260]
53. Crotty B, Rosenberg WM, Aronson JK, Jewell DP. Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease. *Gut* 1992; 33(10): 1353-7. [PMID: 1446859]
54. Brearley CJ, Wood AJ, Aronson JK, Grahame-Smith DG. Evidence for an altered mode of action of the sodium/lithium countertransporter in vivo in patients with untreated essential hypertension. *J Hypertens* 1993; 11(2): 147-53. [PMID: 8385174]
55. Aronson JK, Chappell MJ, Godfrey KR, Yew MK. Modelling circadian variation in the pharmacokinetics of non-steroidal anti-inflammatory drugs. *Eur J Clin Pharmacol* 1993; 45(4): 357-61. [PMID: 8299670]
56. Brearley CJ, Aronson JK, Boon NA, Raine AEG. Effects of haemodialysis and continuous ambulatory peritoneal dialysis on abnormalities of ion transport in vivo in patients with chronic renal failure. *Clin Sci (Lond)* 1993; 85(6): 725-31. [PMID: 8287666]
57. Aronson JK. What's in a brand name? *BMJ* 1994; 308(6937): 1140-1. [PMID: 8173456]
58. Aronson JK. The imp in the bottle. *Practitioner* 1994; 238(1544): 792-4. [PMID: 7991498]
59. Antia IJ, Smith CE, Wood AJ, Aronson JK. The upregulation of Na^+, K^+ -ATPase pump numbers in lymphocytes from the first-degree unaffected relatives of patients with manic depressive psychosis in response to in vitro lithium and sodium ethacrynate. *J Affect Disord* 1995; 34(1): 33-9. [PMID: 7622737]
60. Buckley CD, Aronson JK. Prolonged half-life of verapamil in a case of overdose: implications for therapy. *Br J Clin Pharmacol* 1995; 39: 680-3. [PMID: 7654488]
61. Smith CC, Bennett PM, Pearce HM, Harrison PI, Reynolds DJM, Aronson JK, Grahame-Smith DG. Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. *Br J Clin Pharmacol* 1996; 42(4): 423-9. [PMID: 8904613]
62. De Silva HA, Carver JG, Aronson JK. Effects of high external concentrations of K^+ on $^{86}\text{Rb}^+$ efflux in human platelets: evidence for $\text{Na}^+/\text{K}^+ / 2\text{Cl}^-$ co-transport. *Clin Sci (Lond)* 1996; 91(6): 725-31. [PMID: 8976808]

63. Farooqi IS, Aronson JK. Iatrogenic chest pain: a case of 5-fluorouracil cardiotoxicity. *QJM* 1996; 89(12): 953-5. [PMID: 9015489]
64. De Silva HA, Aronson JK. Evidence for an R(+)-[(dihydroindenyl)oxy]alkanoic acid-sensitive K⁺/Cl⁻ co-transporter in human platelets and its interaction with the Na⁺/K⁺/2Cl⁻ co-transporter. *Clin Sci (Lond)* 1997; 93(3): 243-8. [PMID: 9337639]
65. De Silva HA, Carver JG, Aronson JK. Pharmacological evidence of calcium-activated and voltage-gated potassium channels in human platelets. *Clin Sci (Lond)* 1997; 93(3): 249-55. [PMID: 9337640]
66. De Silva HA, Aronson JK, Grahame-Smith DG, Jobst KA, Smith AD. Abnormal function of potassium channels in the platelets of patients with Alzheimer's disease. *Lancet* 1998; 352(9140): 1590-3. [PMID: 9843105]
67. Mendes Ribiero ACM, Brunini TMC, Yaqoob M, Aronson JK, Mann GE, Ellory JC. Identification of system y^L as the high affinity transporter for L-arginine in human platelets: upregulation of L-arginine influx in uraemia. *Pflügers Arch Eur J Pharmacol* 1999; 438(4): 573-5. [PMID: 10519154]
68. Aronson JK. "Where name and image meet"—the argument for "adrenaline" *BMJ* 2000; 320(7233): 506-9. [PMID: 10678871]
69. Nobel CSI, Aronson JK, van den Dobbelsteen DJ, Slater AFG. Inhibition of Na⁺/K⁺-ATPase may be one mechanism contributing to potassium efflux and cell shrinkage in CD95-induced apoptosis. *Apoptosis* 2000; 5(2): 153-63. [PMID: 11232243]
70. Haeseler G, Mamarvar M, Bufler J, Dengler R, Hecker H, Aronson JK, Piepenbrock S, Leuwer M. Voltage-dependent blockade of normal and mutant muscle sodium channels by benzylalcohol. *Br J Pharmacol* 2000; 130(6): 1321-30. [PMID: 10903972]
71. Haeseler G, Piepenbrink A, Bufler J, Dengler R, Hecker H, Aronson JK, Piepenbrock S, Leuwer M. Phenol derivatives accelerate inactivation kinetics in one inactivation-deficient mutant human skeletal muscle Na⁺ channel. *Eur J Pharmacol* 2001; 416(1-2): 11-18. [PMID: 11282107]
72. Haeseler G, Piepenbrink A, Bufler J, Dengler R, Aronson JK, Piepenbrock S, Leuwer M. Structural requirements for voltage-dependent block of muscle sodium channels by phenol derivatives. *Br J Pharmacol* 2001; 132(8): 1916-24. [PMID: 11309264]
73. Derry S, Loke YK, Aronson JK. Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. *BMC Med Res Methodol* 2001; 1: 7. <http://www.biomedcentral.com/1471-2288/1/7/> Epub 2001 Sep 3. [PMID: 11591220]
74. Aronson JK, Loke Y, Derry S. Adverse drug reactions: keeping up to date. *Fundam Clin Pharmacol* 2002; 16(1): 49-56. [PMID: 11903512]
75. Haeseler G, Bufler J, Merken S, Dengler R, Aronson JK, Leuwer M. Block of voltage-operated sodium channels by 2,6-dimethylphenol, a structural analogue of lidocaine's aromatic tail. *Br J Pharmacol* 2002; 137(2): 285-93. [PMID: 12208786]
76. de Silva HA, Fonseka MMD, Pathmeswaran A, Alahakoon DGS, Ratnatilake GA, Gunatilake SB, Ranasinha CD, Lalloo DG, Aronson JK, de Silva HJ. Multiple-dose activated charcoal for treatment of yellow oleander poisoning: a single-blind, randomized, placebo-controlled trial. *Lancet* 2003; 361(9373): 1935-8. [PMID: 12801736]
77. Aronson JK, Ferner RE. Joining the DoTS. New approach to classifying adverse drug reactions. *BMJ* 2003; 327(7425): 1222-5. [PMID: 14630763]
78. Maxwell S, Walley T; BPS Clinical Section Committee. Teaching safe and effective prescribing in UK medical schools: a core curriculum for tomorrow's doctors. *Br J Clin Pharmacol* 2003; 55(6): 496-503. [PMID: 12814441]
79. Leuwer M, Haeseler G, Hecker H, Bufler J, Dengler R, Aronson JK. An improved model for the binding of lidocaine and structurally related local anaesthetics to fast-inactivated voltage-operated sodium channels, showing evidence of cooperativity. *Br J Pharmacol* 2004; 141(1): 47-54. [PMID: 14662728]
80. Loke YK, Derry S, Aronson JK. A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone. *Br J Clin Pharmacol* 2004; 57(5): 616-21. [PMID: 15089815]
81. Ferner RE, Aronson JK. National differences in publishing reports of adverse drug reactions. *Br J Clin Pharmacol* 2005; 59(1): 108-11. [PMID: 15606448]
82. Aronson JK. Unity from diversity: the evidential use of anecdotal reports of adverse drug reactions and interactions. *J Eval Clin Pract* 2005; 11(2): 195-208. [PMID: 15813716]
83. Haeseler G, Ahrens J, Krampfl K, Bufler J, Dengler R, Hecker H, Aronson JK, Leuwer M. Structural features of phenol derivatives determining potency for activation of chloride currents via alpha(1) homomeric and alpha(1)beta heteromeric glycine receptors. *Br J Pharmacol* 2005; 145(7): 916-25. [PMID: 15912136]

84. Aronson JK, Ferner RE. Clarification of terminology in drug safety. *Drug Saf* 2005; 28(10): 851-70. [PMID: 16180936]
85. Loke YK, Price D, Derry S, Aronson JK. Case reports of suspected adverse drug reactions—systematic literature survey of follow-up. *BMJ* 2006; 332(7537): 335-9. Epub 2006 Jan 18. [PMID: 16421149]
86. Ferner RE, Aronson JK. Communicating information about drug safety. *BMJ* 2006; 333(7559): 143-5. [PMID: 16840480]
87. Ferner RE, Aronson JK. Clarification of terminology in medication errors: definitions and classification. *Drug Saf* 2006; 29(11): 1011-22. [PMID: 17061907]
88. Aronson JK, Hauben M. Anecdotes that provide definitive evidence. *BMJ* 2006; 332(7581): 1267-9. [PMID: 17170419]
89. Hauben M, Aronson JK. Gold standards in pharmacovigilance: the use of definitive anecdotal reports of adverse drug reactions as pure gold and high grade ore. *Drug Saf* 2007; 30(8): 645-55. [PMID: 17696577]
90. Loke YK, Price D, Herxheimer A; the Cochrane Adverse Effects Methods Group. Systematic reviews of adverse effects: framework for a structured approach. *BMC Med Res Methodol* 2007; 7 July: 32. [PMID: 17615054]
91. Lechler R, Paice E, Hays R, Petty-Saphon K, Aronson JK, Bramble M, Hughes I, Rigby E, Anwar Q, Webb D, Maxwell S, Martin J, Maskrey N, Walker S. Outcomes of the Medical Schools Council Safe Prescribing Working Group, 2007. <http://www.medschools.ac.uk/News/Pages/Safe-Prescribing-Working-Group.aspx>
92. Aronson JK, Price D, Ferner RE. A strategy for regulatory action when new adverse effects of a licensed product emerge. *Drug Saf* 2009; 32(2): 91-8. doi: 10.2165/00002018-200932020-00002. [PMID: 19236116]
93. Hauben M, Aronson JK. Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions. *Drug Saf* 2009; 32(2): 99-110. doi: 10.2165/00002018-200932020-00003. [PMID: 19236117]
94. Howick J, Glasziou P, Aronson JK. The evolution of evidence hierarchies: what can Bradford Hill's 'guidelines for causation' contribute? *J R Soc Med* 2009; 102(5): 186-94. [PMID: 19417051]
95. Members of EMERGE, the Erice Medication Errors Research Group; Agrawal A, Aronson JK, Britten N, Ferner RE, de Smet PA, Fialová D, Fitzgerald RJ, Likić R, Maxwell SR, Meyboom RH, Minuz P, Onder G, Schachter M, Velo G. Medication errors: problems and recommendations from a consensus meeting. *Br J Clin Pharmacol* 2009; 67(6): 592-8. [PMID: 19594525]
96. Barkun JS, Aronson JK, Feldman LS, Maddern GJ, Strasberg SM; Balliol Collaboration, Altman DG, Barkun JS, Blazeby JM, Boutron IC, Campbell WB, Clavien PA, Cook JA, Ergina PL, Flum DR, Glasziou P, Marshall JC, McCulloch P, Nicholl J, Reeves BC, Seiler CM, Meakins JL, Ashby D, Black N, Bunker J, Burton M, Campbell M, Chalkidou K, Chalmers I, de Leval M, Deeks J, Grant A, Gray M, Greenhalgh R, Jenicek M, Kehoe S, Lilford R, Littlejohns P, Loke Y, Madhock R, McPherson K, Rothwell P, Summerskill B, Taggart D, Tekkis P, Thompson M, Treasure T, Trohler U, Vandenbroucke J. Surgical Innovation and Evaluation. 1. Evaluation and stages of surgical innovations. *Lancet* 2009; 374(9695): 1089-96. [PMID: 19782874]
97. Ergina PL, Cook JA, Blazeby JM, Boutron I, Clavien PA, Reeves BC, Seiler CM; Balliol Collaboration, Altman DG, Aronson JK, Barkun JS, Campbell WB, Cook JA, Feldman LS, Flum DR, Glasziou P, Maddern GJ, Marshall JC, McCulloch P, Nicholl J, Strasberg SM, Meakins JL, Ashby D, Black N, Bunker J, Burton M, Campbell M, Chalkidou K, Chalmers I, de Leval M, Deeks J, Grant A, Gray M, Greenhalgh R, Jenicek M, Kehoe S, Lilford R, Littlejohns P, Loke Y, Madhock R, McPherson K, Rothwell P, Summerskill B, Taggart D, Tekkis P, Thompson M, Treasure T, Trohler U, Vandenbroucke J. Surgical Innovation and Evaluation. 2. Challenges in evaluating surgical innovation. *Lancet* 2009; 374(9695): 1097-104. [PMID: 19782876]
98. McCulloch P, Altman DG, Campbell WB, Flum DR, Glasziou P, Marshall JC, Nicholl J; Balliol Collaboration, Aronson JK, Barkun JS, Blazeby JM, Boutron IC, Campbell WB, Clavien PA, Cook JA, Ergina PL, Feldman LS, Flum DR, Maddern GJ, Nicholl J, Reeves BC, Seiler CM, Strasberg SM, Meakins JL, Ashby D, Black N, Bunker J, Burton M, Campbell M, Chalkidou K, Chalmers I, de Leval M, Deeks J, Ergina PL, Grant A, Gray M, Greenhalgh R, Jenicek M, Kehoe S, Lilford R, Littlejohns P, Loke Y, Madhock R, McPherson K, Meakins J, Rothwell P, Summerskill B, Taggart D, Tekkis P, Thompson M, Treasure T, Trohler U, Vandenbroucke J. Surgical Innovation and Evaluation. 3. No surgical innovation without evaluation: the IDEAL recommendations. *Lancet* 2009; 374(9695): 1105-12. [PMID: 19782875]

99. Hughes DA, Aronson JK. A systematic review and empirical analysis of the relation between dose and duration of drug action. *J Clin Pharmacol* 2010; 50(1): 17-26. Epub 2009 Oct 1. [PMID: 19797537]
100. Ferner RE, Aronson JK. EIDOS: A mechanistic classification of adverse drug effects. *Drug Saf* 2010; 33(1): 15-23. doi: 10.2165/11318910-000000000-00000. [PMID: 20000863]
101. Ferner RE, Hughes DA, Aronson JK. NICE and new: appraising innovation. *BMJ* 2010; 340: b5493. doi: 10.1136/bmj.b5493. [PMID: 20051468]
102. Aronson JK. A manifesto for clinical pharmacology from principles to practice. *Br J Clin Pharmacol* 2010; 70(1): 3-13. [PMID: 20642541]
103. Ferner RE, Aronson JK. Preventability of drug-related harms. Part 1: A systematic review. *Drug Saf* 2010; 33(11): 985-94. doi: 10.2165/11538270-000000000-00000. [PMID: 20925436]
104. Aronson JK, Ferner RE. Preventability of drug-related harms. Part 2: Proposed criteria, based on frameworks that classify adverse drug reactions. *Drug Saf* 2010; 33(11): 995-1002. doi: 10.2165/11538280-000000000-00000. [PMID: 20925437]
105. Howick J, Glasziou P, Aronson JK. Evidence-based mechanistic reasoning. *J R Soc Med* 2010; 103(11): 433-41. [PMID: 21037334]
106. Aronson JK. How to attract, retain, and nurture young academic clinicians: lessons from Peter B Medawar and James D Watson. *J R Soc Med* 2011; 104(1): 6-14. [PMID: 21205772]
107. Buclin T, Telenti A, Perera R, Csajka C, Furrer H, Aronson JK, Glasziou PP. Development and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapy. *PLoS One* 2011; 6(4): e18578. [PMID: 21494630]
108. De Silva HA, Pathmeswaran A, Ranasinha CD, Jayamanne S, Samarakoon SB, Hittharage A, Kalupahana R, Ratnatilaka GA, Uluwathage W, Aronson JK, Armitage JM, Lalloo DG, De Silva HJ. Low-dose adrenaline, promethazine and hydrocortisone in the prevention of acute adverse reactions to antivenom following snakebite: a randomised, double blind, placebo-controlled trial. *PLoS Med* 2011; 8(5): e1000435. Epub 2011 May 10. [PMID: 21572992]
109. Aronson JK. What do clinical pharmacologists do? A questionnaire survey of senior UK clinical pharmacologists. *Br J Clin Pharmacol* 2012; 73(2): 161-9. Epub 2011 Aug 10. doi: 10.1111/j.1365-2125.2011.04079.x [PMID: 21831197]
110. Barker CIS, Talbot JCC, Aronson JK. Selected national pharmacovigilance websites. An analysis of contents. *Drug Saf* 2012; 35(2): 141-8. doi: 10.2165/11596270-000000000-00000. [PMID: 22168572]
111. Smith SW, Hauben M, Aronson JK. Paradoxical and bidirectional drug effects. *Drug Saf* 2012; 35(3): 173-89. doi: 10.2165/11597710-000000000-00000. [PMID: 22272687]
112. Aronson JK, Hauben M, Bate A. Defining "surveillance" in drug safety. *Drug Saf* 2012; 35(5): 1-11. [PMID: 22462653]
113. Aronson JK, Ferner RE, Hughes DA. Defining rewardable innovation in drug therapy. *Nat Rev Drug Discov* 2012; 11(4): 253-4. doi: 10.1038/nrd3715. [PMID: 22460109]
114. Vrijens B, De Geest S, Hughes D, Kardas P, Demonceau J, Ruppert T, Dobbels F, Fargher E, Morrison V, Lewek P, Matyjaszczuk M, Mshelia C, Clyne W, Aronson JK, Urquhart J; ABC project team. A new taxonomy for describing and defining adherence to medications. *Br J Clin Pharmacol* 2012; 73(5): 691-705. doi: 10.1111/j.1365-2125.2011.04167.x. [PMID: 22486599]
115. Aronson JK. Distinguishing hazards and harms, adverse drug effects and adverse drug reactions: implications for clinical trials, biomarkers, monitoring, and surveillance. *Drug Saf* 2013; 36(3): 147-53. DOI: 10.1007/s40264-013-0019-9
116. McDowell SE, Thomas SK, Coleman JJ, Aronson JK, Ferner RE. A practical guide to monitoring for adverse drug reactions during antihypertensive drug therapy. *J R Soc Med* 2013; 106(3): 87-95. doi: 10.1258/jrsm.2012.120137. [PMID: 23481430]
117. Howick J, Glasziou P, Aronson JK. Can understanding mechanisms solve the problem of extrapolating from study to target populations (the problem of "external validity")? *J R Soc Med* 2013; 106(3): 81-6. [PMID: 23481429]
118. Taylor KS, Heneghan CJ, Farmer AJ, Fuller AM, Adler AI, Aronson JK, Stevens RJ. All-cause and cardiovascular mortality in middle-aged people with type 2 diabetes compared with people without diabetes in a large UK primary care database. *Diabetes Care* 2013; 36(8): 2366-7. [Epub ahead of print Feb 22]. [PMID: 23435157]
119. Howick J, Glasziou P, Aronson JK. Problems with using mechanisms to solve the problem of extrapolation. *Theor Med Bioeth* 2013; 34(4): 275-91. [PMID: 23860640]
120. Ferner RE, Aronson JK. Laughter and MIRTH (Methodical Investigation of Risibility, Therapeutic and Harmful): a narrative synthesis. *BMJ* 2013; 347: f7274. [PMID: 24336308] See also

- <http://well.blogs.nytimes.com/2013/12/20/who-says-laughters-the-best-medicine/?ref=janhoffman&r=0>; <http://www.birminghammail.co.uk/news/local-news/university-birmingham-research-found-laughter-6407967>. Also; translated into Portuguese: Porto Fajardo A, Ramos Reuillard PC. A tradução de expressões metafóricas em um texto especializado do campo da saúde. *Cultura & Tradução*. João Pessoa 2014; 3(1): 122-33
121. Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D; the CARE Group. The CARE guidelines: consensus-based clinical case report guideline development. Published simultaneously in: *Glob Adv Health Med* 2013; 2(5): 38-43 [PMID: 24416692]; *Dtsch Arztebl Int* 2013; 110(37): 603-8 [PMID: 24078847]; *J Med Case Rep* 2013; 7(1): 223 [PMID: 24228906]; *BMJ Case Rep* 2013; 2013. pii: bcr2013201554 [PMID: 24155002]; *Headache* 2013; 53(10): 1541-7 [PMID: 24266334]; *J Diet Suppl* 2013; 10(4): 381-90 [PMID: 24237192]; *J Clin Epidemiol* 2014; 67(1): 46-51 [PMID: 24035173]
 122. Floor-Schreuderling A, Geerts AFJ, Aronson JK, Bouvy ML, Ferner RE, De Smet PAGM. Checklist for standardized reporting of drug-drug interaction management guidelines. *Eur J Clin Pharmacol* 2014; 70(3): 313-8. [Epub ahead of print 2013 Dec 5] [PMID: 24306496]
 123. Hirst JA, Howick J, Aronson JK, Roberts N, Perera R, Koshiaris C, Heneghan C. The need for randomization in animal trials: an overview of systematic reviews. *PLoS One* 2014; 9(6): e98856. [PMID: 24906117]
 124. Dorrington K, Aronson JK. Failed phlebotomy? Think William Harvey. *BMJ* 2014; 349: g5232
 125. Hodder A, Huntley C, Aronson JK, Ramachandran M. Pycnodysostosis and the making of an artist. *Gene* 2014 Sep 30. pii: S0378-1119(14)01109-3
 126. Hirst JA, Farmer AJ, Feakins BG, Aronson JK, Stevens RJ. Quantifying the effects of diuretics and beta-blockers on glycaemic control in diabetes mellitus—a systematic review and meta-analysis. *Br J Clin Pharmacol* 2014; 79(5): 33-43. doi: 10.1111/bcp.12543. [PMID: 25377481]
 127. Onakpoya IJ, Heneghan CJ, Aronson JK. Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis. *BMC Medicine* 2015; 13: 26. doi: 10.1186/s12916-014-0262-7. <http://www.biomedcentral.com/1741-7015/13/26>. doi: 10.1186/s12916-014-0262-7. <http://www.biomedcentral.com/1741-7015/13/26>
 128. Aronson JK. Towards standardized reporting of drug interactions—the READI checklist for anecdotal reports. *Exp Rev Clin Pharmacol* 2015; 8(4): 399-409
 129. Ferner RE, Aronson JK. Cato Guldberg & Peter Waage, the history of the Law of Mass Action, and its relevance to clinical pharmacology. *Br J Clin Pharmacol* 2016; 81(1): 52-5. doi: 10.1111/bcp.12721. [IF 3.830] <http://www.ncbi.nlm.nih.gov/pubmed/26174880>
 130. Aronson JK, Ferner RE. The Law of Mass Action and the pharmacological concentration-effect curve: resolving the paradox of apparently non-dose-related adverse drug reactions. *Br J Clin Pharmacol* 2015; 81(1): 56-61. doi: 10.1111/bcp.12706.
 131. Perregaard H, Aronson JK, Dalhoff K, Hellebek A. Medication errors in patients taking low-dose methotrexate. A national survey based on four different registers. *Eur J Clin Pharmacol* 2015; 71(11): 1375-9. doi: 10.1007/s00228-015-1910-3. Epub 2015 Aug 11
 132. Bryan R, Aronson JK, ten Hacken P, Williams A, Jordan S. Patient safety in medication nomenclature: orthographic and semantic properties of international nonproprietary names. *PLoS One* 2015; 10(12): e0145431. doi: 10.1371/journal.pone.0145431. eCollection 2015
 133. Hauben M, Aronson JK, Ferner RE. Evidence of misclassification of drug-event associations classified as gold-standard 'negative controls' by the Observational Medical Outcomes Partnership (OMOP). *Drug Saf* 2016; 39(5): 421-32. doi: 10.1007/s40264-016-0392-2
 134. Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. *BMC Med* 2016; 14: 10. doi: 10.1186/s12916-016-0553-2
 135. Onakpoya IJ, Heneghan CJ, Aronson JK. Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis. *Crit Rev Toxicol* 2016; Mar 3: 1-13. <http://dx.doi.org/10.3109/10408444.2016.1149452>
 136. Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes T, Cipriani A, Coghill DR, Fazel S, Geddes JR, Grunze H, Holmes EA, Howes O, Hudson S, Hunt N, Jones I, Macmillan IC, McAllister-Williams H, Miklowitz DR, Morriss R, Munafò M, Paton C, Saharkian BJ, Saunders K, Sinclair J, Taylor D, Vieta E, Young AH. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. *J Psychopharmacol* 2016; 30(6): 495-553. doi: 10.1177/0269881116636545. Epub 2016 Mar 15
 137. Aronson JK. Defining “nutraceuticals”: neither nutritious nor pharmaceutical. *Br J Clin Pharmacol* 2016 Mar 16. doi: 10.1111/bcp.12935. [Epub ahead of print]

138. Langford O, Aronson JK, van Valkenhoef G, Stevens RJ. Methods for meta-analysis of pharmacodynamic dose-response data with application to multi-arm studies of alogliptin. *Stat Methods Med Res* 2016 Mar 17. pii: 0962280216637093. [Epub ahead of print]
139. Aronson JK. "Collaborative care" is preferable to "patient centred care" *BMJ* 2016; 353: i2926. doi: 10.1136/bmj.i2926
140. Agha RA, Fowler AJ, Saeta A, Barai I, Rajmohan S, Orgill DP; The SCARE Group: Afifi R, Al-Ahmadi R, Albrecht J, Alsawadi A, Aronson JK, Ather MH, Bashashati M, Basu S, Bradley P, Chalkoo M, Challacombe B, Cross T, Derbyshire L, Farooq N, Hoffman J, Kadioglu H, Kasivisvanathan V, Kirshtein B, Klappenbach R, Laskin D, Miguel D, Milburn J, Mousavi SR, Muensterer O, Nguac J, Nixon I, Noureldin A, Perakath B, Raison N, Raveendran K, Sullivan T, Thoma A, Thorat M, Valmasoni M, Massarut S, D'cruz A, Baskaran V, Giordano S, Royaq G, Machado-Aranda D, Healy D, Carroll B, Rosin D. The SCARE guidelines: Consensus-based surgical case report guidelines. *Int J Surg* 2016; in press
141. Hirst JA, Aronson JK, Feakins BG, Ma C, Farmer AJ, Stevens RJ. Short and medium-term effects of moderate alcohol intake on glycaemic control in diabetes mellitus - a systematic review and meta-analysis of randomised trials. *Diabetic Med* 2016; in press

A1 Published protocols

1. Hirst J, Aronson J, Farmer A, Bankhead C, Stevens R. A systematic review of the effect of non-diabetes medications on glycaemic control. PROSPERO 8 April 2013:CRD42013004261 http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42013004261
2. Hirst J, Stevens R, Feakins B, Aronson J, Farmer A. Protocol for systematic review and meta-analysis of the effects of alcohol on glycaemic control in diabetes. PROSPERO 17 March 2014:CRD42014008806. http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42014008806
3. Onakpoya I, Spencer E, Heneghan C, Aronson J. Drop-out rates in randomized clinical trials comparing natural versus synthetic statins: a systematic review and meta-analysis. PROSPERO 10 August 2015: CRD42015024325. http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015024325
4. Hansen MP, Thorning S, Aronson JK, Beller EM, Glasziou PP, Hoffmann TC, Del Mar CB. Adverse events in patients taking macrolide antibiotics versus placebo for any indication (Protocol). *The Cochrane Library*. 2015; 8. <https://archie.cochrane.org/sections/reviews/wileyPDF?documentVersion PK=z1507302306579648887043042825782>

B Books and edited journal issues

1. Grahame-Smith DG, Aronson JK. *The Oxford Textbook of Clinical Pharmacology and Drug Therapy*. Oxford University Press, 1984. ISBN 0-19-261172-0 (paperback); 0-19-261492-4 (cased); 0-19-442426-X (paperback ELBS edition)
2. Dukes MNG, editor, Aronson JK, Blackwell B, Elis J, Folb PI, Hoigné R, Hvidberg EF, Lunde PKM, Tester-Dalderup CBM, von Eickstedt K-W, Westerholm B, co-editors. *Meyler's Side Effects of Drugs*. 10th edition. Amsterdam: Elsevier, 1984. ISBN 0-444-90323-2
3. Aronson JK. *An Account of The Foxglove and its Medical Uses 1785-1985*. Oxford: Oxford University Press, 1985 [incorporating a facsimile of William Withering's monograph 'An account of the foxglove' (1785) in a specially annotated edition]. ISBN 0-19-261501-7. [Spanish translation by D Mario Petit Guinovart & Juan Hernández Herrero, 1988.]
4. Dukes MNG, editor, Aronson JK, Blackwell B, Dittmann S, Folb PI, Hoigné R, Hvidberg EF, Tester-Dalderup CBM, Tognoni G, von Eickstedt K-W, Westerholm B, co-editors. *Meyler's Side Effects of Drugs*. 11th edition. Amsterdam: Elsevier, 1988. ISBN 0-444-90484-0
5. Dukes MNG, Aronson JK, editors. *Side Effects of Drugs, Annual 15*. Amsterdam: Elsevier, 1991. ISSN 0378-6080
6. Grahame-Smith DG, Aronson JK. *The Oxford Textbook of Clinical Pharmacology and Drug Therapy*. Second edition. Oxford: Oxford University Press, 1992. ISBN 0-19-261676-5 (hardback); 0-19-261675-7 (paperback)
7. Dukes MNG, editor, Aronson JK, Blackwell B, Dittmann S, Folb PI, Hoigné R, Hvidberg EF, Tester-Dalderup CBM, Tognoni G, von Eickstedt K-W, Westerholm B, co-editors. *Meyler's Side Effects of Drugs*. 12th edition. Amsterdam: Elsevier, 1992. ISBN 0-444-89524-8
8. Dukes MNG, Aronson JK, editors. *Side Effects of Drugs, Annual 16*. Amsterdam: Elsevier, 1992. ISBN 0-444-89657-0. ISSN 0378-6080

9. Aronson JK, Hardman M, Reynolds DJM. ABC of Monitoring Drug Therapy. London: BMJ Publishing Group, 1993. ISBN 0-727-907913
10. Aronson JK, Van Boxtel CJ, editors. Side Effects of Drugs, Annual 17. Amsterdam: Elsevier, 1993. ISBN 0-444-82005-1. ISSN 0378-6080
11. Aronson JK, Van Boxtel CJ, editors. Side Effects of Drugs, Annual 18. Amsterdam: Elsevier, 1994. ISBN 0-444-81939-8. ISSN 0378-6080
12. Aronson JK, Van Boxtel CJ, editors. Side Effects of Drugs, Annual 19. Amsterdam: Elsevier, 1996. ISBN 0-444-82531-2. ISSN 0378-6080
13. Dukes MNG, editor, Aronson JK, Folb PI, Hoigné R, Lunde PKM, Tester-Dalderup CBM, Van Boxtel CJ, Vrhovac B, co-editors. Meyler's Side Effects of Drugs. 13th edition. Amsterdam: Elsevier, 1996. ISBN 0-444-82405-7
14. Aronson JK, editor. Side Effects of Drugs, Annual 20. Amsterdam: Elsevier, 1997. ISBN 0-444-82532-0. ISSN 0378-6080
15. Aronson JK, editor. Side Effects of Drugs, Annual 21. Amsterdam: Elsevier, 1998. ISBN 0-444-82818-4. ISSN 0378-6080
16. Aronson JK, editor. Side Effects of Drugs, Annual 22. Amsterdam: Elsevier, 1999. ISBN 0-444-50092-8. ISSN 0378-6080
17. Aronson JK, editor. Side Effects of Drugs, Annual 23. Amsterdam: Elsevier, 2000. ISBN 0-444-50212-2. ISSN 0378-6080
18. Dukes MNG, Aronson JK, editors. Meyler's Side Effects of Drugs. An Encyclopedia of Adverse Reactions and Interactions. 14th edition. Amsterdam: Elsevier, 2000. ISBN 0-444-50993-6
19. Aronson JK, editor. Side Effects of Drugs, Annual 24. Amsterdam: Elsevier, 2001. ISBN 0-444-50512-1. ISSN 0378-6080
20. Grahame-Smith DG, Aronson JK. The Oxford Textbook of Clinical Pharmacology and Drug Therapy. Third edition. Oxford: Oxford University Press, 2002. ISBN 0-19-850944-8 (hardback); 0-19-263234-5 (paperback)
21. Aronson JK, editor. Side Effects of Drugs Annual 25. Amsterdam: Elsevier, 2002. ISBN 0-444-50674-8. ISSN 0378-6080
22. Aronson JK, editor. Side Effects of Drugs Annual 26. Amsterdam: Elsevier, 2003. ISBN 0-444-50999-2. ISSN 0378-6080
23. Aronson JK, editor. Side Effects of Drugs Annual 27. Amsterdam: Elsevier, 2004. ISBN 0-444-51356-6. ISSN 0378-6080
24. Cuervo LG, Aronson JK editors. BMJ special issue: "Balancing benefits and harms in health care", 3 July 2004
25. Aronson JK editor. British Journal of Clinical Pharmacology special issue: "Citation Classics in the British Journal of Clinical Pharmacology, 1974-2003", December 2004
26. Richards DB, Aronson JK. The Oxford Handbook of Practical Drug Therapy. Oxford: Oxford University Press, 2005. ISBN 0-19-853007-2
27. Aronson JK, editor. Side Effects of Drugs Annual 28. Amsterdam: Elsevier, 2005. ISBN 0-444-51571-2. ISSN 0378-6080
28. Aronson JK editor. British Journal of Clinical Pharmacology special issue: "Clinical Pharmacology: Past, Present, and Future", June 2006
29. Aronson JK, editor. Meyler's Side Effects of Drugs—The International Encyclopedia of Adverse Drug Reactions and Interactions, 15th edition (6 volumes). Amsterdam: Elsevier, 2006. ISBN 978-044-50998-7
30. Aronson JK editor. British Journal of Clinical Pharmacology special issue: "Adverse Drug Reactions", February 2007
31. Aronson JK, editor. Side Effects of Drugs, Annual 29. Amsterdam: Elsevier, 2007. ISBN 978-0-444-51986-3. ISSN 0378-6080
32. Glasziou P, Irwig L, Aronson JK, editors. Evidence-based Medical Monitoring: From Principles to Practice. Oxford: Blackwell Publishing/BMJ Books, 2008. ISBN 978-1-4051-5399-7
33. Aronson JK, editor. Side Effects of Drugs, Annual 30. Amsterdam: Elsevier, 2008. ISBN 978-0-444-52767-7. ISSN 0378-6080
34. Aronson JK, editor. Meyler's Side Effects of Herbal Medicines. Amsterdam: Elsevier, 2008. ISBN 978-044-453269-5
35. Aronson JK, editor. Meyler's Side Effects of Psychiatric Drugs. Amsterdam: Elsevier, 2008. ISBN 978-044-453266-4
36. Aronson JK, editor. Meyler's Side Effects of Drugs Used in Anesthesia. Amsterdam: Elsevier, 2008. ISBN 978-044-453270-1

37. Aronson JK, editor. *Meyler's Side Effects of Cardiovascular Drugs*. Amsterdam: Elsevier, 2008. ISBN 978-044-453268-8
38. Aronson JK, editor. *Meyler's Side Effects of Endocrine and Metabolic Drugs*. Amsterdam: Elsevier, 2008. ISBN 978-044-453271-8
39. Aronson JK editor. *British Journal of Clinical Pharmacology* special issue: "Medication Errors", June 2009
40. Aronson JK, editor. CME: Clinical pharmacology. *Clinical Medicine* 2009; 9(5): 478-97
41. Aronson JK, editor. *Side Effects of Drugs, Annual 31*. Amsterdam: Elsevier, 2009. ISBN 978-0-444-53294-7. ISSN 0378-6080
42. Aronson JK, editor. *Meyler's Side Effects of Antimicrobial Drugs*. Amsterdam: Elsevier, 2010. ISBN 978-044-453272-5
43. Aronson JK, editor. *Meyler's Side Effects of Analgesics and Anti-inflammatory Drugs*. Amsterdam: Elsevier, 2010. ISBN 978-044-453273-2
44. Aronson JK, editor. *Meyler's Side Effects of Drugs in Cancer and Immunology*. Amsterdam: Elsevier, 2010. ISBN 978-044-453267-1
45. Ramachandran M, Aronson JK. *Doctoring History*. London: Royal Society of Medicine, 2010. ISBN 978-1-85315-812-4
46. Aronson JK, editor. *Side Effects of Drugs, Annual 32*. Amsterdam: Elsevier, 2010. ISBN 978-0-444-53550-4. ISSN 0378-6080
47. Talbot J, Aronson JK, editors. *Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice*. 6th edition. Oxford: Wiley-Blackwell, 2011. ISBN 978-0-470-98634-9 (cloth); 978-0-470-97504-6 (e-PDF)
48. Richards DB, Coleman JJ, Reynolds DJM, Aronson JK. *The Oxford Handbook of Practical Drug Therapy*. Oxford: Oxford University Press, 2nd edition, 2011. ISBN 978-0-19-956285-5
49. Aronson JK, editor. *Side Effects of Drugs, Annual 33*. Amsterdam: Elsevier, 2011. ISBN 978-0-444-53741-6. ISSN 0378-6080
50. Aronson JK editor. Special issue: "An Agenda for UK Clinical Pharmacology", *British Journal of Clinical Pharmacology* 2012; 73(6): 843-5 and 861-982
51. Aronson JK, editor. *Side Effects of Drugs, Annual 34*. Amsterdam: Elsevier, 2012. ISBN 978-0-444-59499-0. ISSN: 0378-6080. <http://dx.doi.org/10.1016/B978-0-444-59499-0.00002-7>
52. Aronson JK, editor. *Side Effects of Drugs, Annual 35*. Amsterdam: Elsevier, 2014. ISSN: 0378-6080. <http://dx.doi.org/10.1016/B978-0-444-62635-6.00006-1>
53. Aronson JK, editor. *Meyler's Side Effects of Drugs—The International Encyclopedia of Adverse Drug Reactions and Interactions*, 16th edition. Amsterdam: Elsevier, 2016. ISBN 978-0-444-53717-1. <http://www.sciencedirect.com/science/referenceworks/9780444537164>

C Editorial reviews and commentaries—General

1. Anonymous [Aronson JK, Grahame-Smith DG]. Foxglove saga (continued). *Lancet* 1976; 2(7982): 405. [PMID: 73859]
2. Aronson JK. Digitalis intoxication. *Clin Sci (Lond)* 1983; 64(3): 253-8. [PMID: 6337012]
3. Aronson JK. Cardiac arrhythmias—theory and practice. *Br Med J (Clin Res Ed)* 1985; 290(6467): 487-8. [PMID: 3918643]
4. Boon NA, Aronson JK. Dietary salt and hypertension—treatment and prevention. *Br Med J (Clin Res Ed)* 1985; 290(6473): 949-50. [PMID: 3919863]
5. Aronson JK, Sear JW. Transdermal hyoscine (scopolamine) and postoperative vomiting. *Anaesthesia* 1986; 41(1): 1-3. [PMID: 3946769]
6. Aronson JK. Glycosides of plants and men. *Med J Aust* 1986; 144(10): 505-6. [PMID: 3713562]
7. Anonymous [Aronson JK]. Administration of drugs by the buccal route. *Lancet* 1987; 1(8534): 666-7. [PMID: 2882088]
8. Anonymous [Aronson JK]. Bepiridil. *Lancet* 1988; 1(8580): 278-9. [PMID: 2893088]
9. Aronson JK, Dengler HJ, Dettli L, Follath F. Standardization of symbols in clinical pharmacology. *Eur J Clin Pharmacol* 1988; 35(1): 1-7. [PMID: 3220089]
10. Aronson JK. Methods for expressing the characteristics of transmembrane ion transport systems. *Clin Sci (Lond)* 1990; 78(3): 247-54. [PMID: 1690620] Comments: Glynn IM & Aronson JK The ambiguity of changes in the rate constant of fluxes. *Clin Sci* 1991; 80(1): 85-6
11. Aronson JK, Ng LL. HMG CoA reductase inhibitors in the treatment of hypercholesterolaemias. *QJM* 1990; 74(274): 111-15. [PMID: 2111916]

12. Smith AJ, Aronson JK, Thomas M. Antibiotics policies in the developing world. *Eur J Clin Pharmacol* 1991; 41(2): 85-7. [PMID: 1743251]
13. Ferner RE, Aronson JK. Errors in prescribing, preparing, and giving medicines—definition, classification, and prevention. In: Aronson JK, editor. *Side Effects of Drugs, Annual 22*. Amsterdam: Elsevier, 1999: xxiii-xxxvi
14. Ferner RE, Aronson JK. Medication errors, worse than a crime. *Lancet* 2000; 355(9208): 947-8. [PMID: 10768430]
15. Aronson JK. Forbidden fruit. *Nat Med* 2001; 7(1): 29-30. [PMID: 11135611]
16. Aronson JK. Anecdotes as evidence. We need guidelines for reporting anecdotes of suspected adverse drug reactions. *BMJ* 2003; 326(7403): 1346. [PMID: 12816800]
17. Aronson JK. PHARMA: Publishing Histories of Adverse Reactions to Medicaments Anecdotally. Reporting suspected adverse drug reactions and interactions: proposed guidelines for authors. <http://bmj.com/cgi/content/full/326/7403/1346/DC1#p>
18. Aronson JK. Being wholistic. *Focus Altern Complement Ther* 2003; 8: 381-2
19. Aronson JK. Live long and prosper: a mass strategy for treating the factors associated with ischaemic heart disease and stroke. *J Med Screen* 2004; 11(1): 1-2. [PMID: 15006105]
20. Cuervo LG, Aronson JK. The road to health care. Balancing benefits and harms of interventions is essential. *BMJ* 2004; 329(7456): 1-2. [PMID: 15231586]
21. Aronson JK. Open access publishing: too much oxygen? *BMJ* 2005; 330(7494): 759. [PMID: 15802718]
22. Aronson JK. Classifying adverse drug reactions in the 21st century. In: Aronson JK, editor. *Side Effects of Drugs, Annual 28*. Amsterdam: Elsevier, 2005: xxvii-xxxiii
23. Aronson JK. "Open-access" publishing: first the evidence—then the verdict. *J R Soc Med* 2006; 99(3): 103-4. [PMID: 16508041]
24. Aronson JK. Commentary on: Chou R, Helfand M. Challenges in systematic reviews that assess treatment harms. *Ann Intern Med* 2005; 142(12 Pt 2): 1090-9. *The Cochrane Collaboration Methods Groups Newsletter* 2006; 10: 8
25. Aronson JK. Polypharmacy, appropriate and inappropriate. *Br J Gen Pract* 2006; 56(528): 484-5. [PMID: 16834872]
26. Aronson JK, Henderson G, Webb DJ, Rawlins MD. A prescription for better prescribing. *BMJ* 2006; 333(7566): 459-60. [PMID: 16946321]
27. Mehta DK, Aronson JK. Give a drug a good name. *Lancet* 2007; 369(9570): 1326-8. [PMID: 17448803]
28. Aronson JK. Something new every day. Defining innovation and innovativeness in drug therapy. *J Ambulatory Care Manage* 2008; 31(1): 65-8. [PMID: 18162799]
29. Aronson JK. PHARMA: Publishing Histories of Adverse Reactions to Medicaments Anecdotally. The PHARMA guidelines for reporting suspected adverse drug reactions. *Drug Saf* 2008; 31(4): 355-6 [PMID: 18366246]
30. Aronson JK. Changing beta-blockers in heart failure: when is a class not a class? *Br J Gen Pract* 2008; 58(551): 387-9. [PMID: 18505613]
31. Aronson JK. Gli errori nell'uso dei farmaci. *Focus Farmacovigilanza* 2008; 53: 1
32. Aronson JK. Drug withdrawals because of adverse effects. In: Aronson JK, editor. *Side Effects of Drugs, Annual 30*. Amsterdam: Elsevier, 2008: xxxi-xxxv
33. Aronson JK. From prescription-only to over-the-counter medicines ('PoM to P'): time for an intermediate category. *Br Med Bull* 2009; 90: 63-9. Epub 2009 May 3. [PMID: 19414447]
34. Aronson JK. Reducing the frequency of medication errors. *EJHP Pract* 2010; 16(4): 61-3
35. Aronson JK. Reducing prescribing errors through medical education. *Prescriber* 2011; 22(8): 6-7
36. Aronson JK. Drug interactions—don't forget herbs, food, and devices. *RIPER PDIC Bull* 2011; 2(16): 7-9
37. Aronson JK, Velo G. Towards a single VOICE for European clinical pharmacology: proposals for future developments. *Eur J Clin Pharmacol* 2013; 69(11):1981-4. [PMID: 23821019]
38. Aronson JK. Observational studies in assessing benefits and harms: double standards? In: Aronson JK, editor. *Side Effects of Drugs, Annual 35*. Amsterdam: Elsevier, 2014: lxxi-lxxxix
39. Aronson JK, Ferner RE. A licence to cure. *BMJ* 2015; 350: h1723. [PMID: 25834026]
40. Aronson JK, Ferner RE. How similar are biosimilars? *BMJ* 2016; 353: i2721

D Editorial commentaries—British Journal of Clinical Pharmacology

1. Aronson JK. Features of this month's *Journal*. [Preventing heart attacks and strokes; complementary medicines; genetic testing.] *Br J Clin Pharmacol* 2003; 55(3): 223-4. [PMCID: PMC1884223]

2. Aronson JK. Features of this month's *Journal*. [Managing reversible airways obstruction.] *Br J Clin Pharmacol* 2003; 55(4): 327-8. [PMCID: PMC1884239]
3. Aronson JK, Lennard MS, Ritter JM, Baber NS, Begg EJ. *The British Journal of Clinical Pharmacology* Editors' Report for 2002. *Br J Clin Pharmacol* 2003; 55(4): 329-30. [PMCID: PMC1884226]
4. Aronson JK. Features of this month's *Journal*. [Teaching drug therapy; adverse effects of selective serotonin reuptake inhibitors; drug-induced QT interval prolongation; Chronopharmacology.] *Br J Clin Pharmacol* 2003; 55(6): 493-4. [PMCID: PMC1884267]
5. Aronson JK. Features of this month's *Journal*. [Uses of population pharmacokinetics; P glycoprotein and cardiac glycosides; khat kinetics.] *Br J Clin Pharmacol* 2003; 56(1): 1-2. [PMCID: PMC1884323]
6. Aronson JK. Features of this month's *Journal*. [Sex and the palpitating heart; age and sedation; ethnicity and blood pressure; ethnicity and cardiovascular disease.] *Br J Clin Pharmacol* 2003; 56(2): 141-2. [PMCID: PMC1884275]
7. Aronson JK. Features of this month's *Journal*. [Old-age medicine; New Age medicine; age and testosterone.] *Br J Clin Pharmacol* 2003; 56(3): 247-8. [PMCID: PMC1884352]
8. Aronson JK. Features of this month's *Journal*. [Keeping up to date; Predicting in vivo events from in vitro studies; Grapes and gripes; Serotonin syndrome in interactions with moclobemide.] *Br J Clin Pharmacol* 2003; 56(4): 347-8. [PMCID: PMC1884370]
9. Aronson JK. Features of this month's *Journal*. [Water under the bridge; Homoeopathy—proving or disproving? One for a man, two for a horse, but how much for a child? *Br J Clin Pharmacol* 2003; 56(5): 475-6. [PMCID: PMC1884404]
10. Aronson JK. Nurse prescribers and reporters. *Br J Clin Pharmacol* 2003; 56(6): 585-7. [PMID: 14616417]
11. Aronson JK. On being 30. *Br J Clin Pharmacol* 2004; 57(1): 1-5. [PMCID: PMC1884412]
12. Aronson JK. In defence of polypharmacy. *Br J Clin Pharmacol* 2004; 57(2): 119-20. [PMID: 14748809]
13. Aronson JK. Rational prescribing, appropriate prescribing. *Br J Clin Pharmacol* 2004; 57(3): 229-30. [PMID: 14998417]
14. Aronson JK. Drug interactions—information, education, and the *British National Formulary*. *Br J Clin Pharmacol* 2004; 57(4): 371-2. [PMID: 15025733]
15. Aronson JK, Lennard MS, Ritter JM, Baber NS, Begg EJ. *The British Journal of Clinical Pharmacology* Editors' Report for 2003. *Br J Clin Pharmacol* 2004; 57(5): 538-9. [PMCID: PMC1884489]
16. Aronson JK. On the waterfront—the breadth and depth of clinical pharmacology. *Br J Clin Pharmacol* 2004; 57(6): 693-4. [PMCID: PMC1884528]
17. Aronson JK. What is a clinical trial? *Br J Clin Pharmacol* 2004; 58(1): 1-3. [PMID: 15206985]
18. Aronson JK. Littluns and biguns. *Br J Clin Pharmacol* 2004; 58(2): 117-18. [PMID: 15255793]
19. Aronson JK. Over-the-counter medicines. *Br J Clin Pharmacol* 2004; 58(3): 231-4. [PMID: 15327581]
20. Aronson JK. Classifying drug interactions. *Br J Clin Pharmacol* 2004; 58(4): 343-4. [PMID: 15373925]
21. Baber NS, Ritter JM, Aronson JK. Medicines regulation and clinical pharmacology. *Br J Clin Pharmacol* 2004; 58(6): 569-70
22. Aronson JK. Citation classics in the *British Journal of Clinical Pharmacology*, 1974–2003. *Br J Clin Pharmacol* 2004; 58(7): S699-702. [PMID: 15595958]
23. Aronson JK, Whelan E. Internationality. *Br J Clin Pharmacol* 2005; 59(1): 1-4. [PMID: 15606433]
24. Aronson JK. Write on. *Br J Clin Pharmacol* 2005; 59(2): 141-2. [PMID: 15676034]
25. Aronson JK. Moving about. *Br J Clin Pharmacol* 2005; 59(3): 263-4. [PMID: 15752370]
26. Aronson JK. Drug development: more science, more education. *Br J Clin Pharmacol* 2005; 59(4): 377-8. [PMID: 15801930]
27. Aronson JK. Biomarkers and surrogate endpoints. *Br J Clin Pharmacol* 2005; 59(5): 491-4. [PMID: 15842546]
28. Aronson JK, Lennard MS, Ritter JM, Begg EJ, Baber NS. Editors' report 2004. *Br J Clin Pharmacol* 2005; 60(1): 5-6
29. Aronson JK. Metameta-analysis. *Br J Clin Pharmacol* 2005; 60(2): 117-19. [PMID: 16042663]
30. Aronson JK. Monitoring therapy. *Br J Clin Pharmacol* 2005; 60(3): 229-30. [PMID: 16120059]
31. Aronson JK. One hundred years of atrial fibrillation. *Br J Clin Pharmacol* 2005; 60(4): 345-6. [PMID: 16187965]
32. Aronson JK. Prescribing statins. *Br J Clin Pharmacol* 2005; 60(5): 457-8. [PMID: 16236034]
33. Aronson JK, Lennard MS, Ritter JM, Baber NS, Begg EJ, Lewis LD. Today's science, tomorrow's medicines. *Br J Clin Pharmacol* 2006; 61(1): 1-4. [PMID: 16390345]
34. Aronson JK. Medicines and the media. *Br J Clin Pharmacol* 2006; 61(2): 121-2. [PMID: 16433865]
35. Aronson JK. Rare diseases and orphan drugs. *Br J Clin Pharmacol* 2006; 61(3): 243-5. [PMID: 16487216]

36. Aronson JK. Monitoring for harms of therapy. *Br J Clin Pharmacol* 2006; 61(4): 365-6. [PMID: 16542195]
37. Aronson JK. A prescription for better prescribing. *Br J Clin Pharmacol* 2006; 61(5): 487-91. [PMID: 16669839]
38. Aronson JK, Lennard MS, Ritter JM, Baber NS, Begg EJ, Lewis LD. Editors' report 2005. *Br J Clin Pharmacol* 2006; 61(5): 492-3. [PMCID: PMC1885061]
39. Aronson JK. Clinical pharmacology: past, present, and future. *Br J Clin Pharmacol* 2006; 61(6): 647-9. [PMID: 16722824]
40. Aronson JK. Risk perception in drug therapy. *Br J Clin Pharmacol* 2006; 62(2): 135-7. [PMID: 16842386]
41. Aronson JK. The NSAID roller coaster: more about rofecoxib. *Br J Clin Pharmacol* 2006; 62(3): 257-9. [PMID: 16934039]
42. Aronson JK. Balanced prescribing. *Br J Clin Pharmacol* 2006; 62(6): 629-32. [PMID: 17118122]
43. Aronson JK, Lennard MS, Ritter JM, Begg EJ, Lewis LD, Schachter M. Editors' review of 2006 and the BJCP prize. *Br J Clin Pharmacol* 2007; 63(1): 1-4. [PMID: 17229039]
44. Aronson JK. Adverse drug reactions—no farewell to harms. *Br J Clin Pharmacol* 2007; 63(2): 131-5. [PMID: 17274787]
45. Aronson JK. Concentration-effect and dose-response relations in clinical pharmacology. *Br J Clin Pharmacol* 2007; 63(3): 255-7. [PMID: 17311674]
46. Aronson JK. Compliance, concordance, adherence. *Br J Clin Pharmacol* 2007; 63(4): 383-4. [PMID: 17378797]
47. Aronson JK. Drug therapy in kidney disease. *Br J Clin Pharmacol* 2007; 63(5): 509-11. [PMID: 17488361]
48. Aronson JK. Communicating information about drug interactions. *Br J Clin Pharmacol* 2007; 63(6): 637-9. [PMCID: PMC2000589]
49. Aronson JK. An agenda for research on adverse drug reactions. *Br J Clin Pharmacol* 2007; 64(2): 119-21. [PMID: 17635504]
50. Aronson JK, Cohen A, Ritter JM, Begg EJ, Lewis LD, Schachter M. Editors' report 2006. *Br J Clin Pharmacol* 2007; 64(3): 253-4. [PMCID: PMC2000648]
51. Aronson JK. Plagiarism—please don't copy. *Br J Clin Pharmacol* 2007; 64(4): 403-5. [PMID: 17880356]
52. Aronson JK. Old drugs—new uses. *Br J Clin Pharmacol* 2007; 64(5): 563-5. [PMID: 17935601]
53. Aronson JK. Time to abandon the term 'patient concordance'. *Br J Clin Pharmacol* 2007; 64(5): 711-3. [PMCID: PMC2203277]
54. Aronson JK, Cohen A, Lewis LD. Review of 2007. Clinical pharmacology—providing tools and expertise for translational medicine. *Br J Clin Pharmacol* 2008; 65(2): 154-7. [PMID: 18251756]
55. Aronson JK. Medication errors—EMERGING solutions. *Br J Clin Pharmacol* 2009; 67(6): 589-91. [PMID: 19594524]
56. Aronson JK. Finding a VOICE for UK Clinical Pharmacology. *Br J Clin Pharmacol* 2012; 73(6): 843-5. doi: 10.1111/j.1365-2125.2012.04233.x. [PMID:22360150]

E Book chapters and reviews

1. Aronson JK. Diuretics and antidiuretics. *MIMS Magazine* 1975; (15): 7-22
2. Aronson JK. The application of digoxin radioimmunoassay in monitoring drug therapy. In: Pasternak C, editor. *Radioimmunoassay in clinical biochemistry*. London: Heyden, 1975: 91-100
3. Youdim MBH, Green AR, Aronson JK. The implications of the effects of tissue iron deficiency on behaviour and drug metabolism. In: Pitcher CS, Richardson RG, editors. *Anaemia in general practice. The place of haematinics*. Abbott, 1977: 37-42
4. Aronson JK. Cardiac glycosides and drugs used in dysrhythmias. In: Dukes MNG, editor. *Side Effects of Drugs, Annual 2*. Amsterdam: Excerpta Medica, 1978: Chapter 17A
5. Grahame-Smith DG, Aronson JK. Assessment of digoxin action by a pharmacodynamic biochemical method. In: Bodem G, Dengler H, editors. *Cardiac glycosides*. Heidelberg: Springer-Verlag, 1978: 242-53
6. Grahame-Smith DG, Aronson JK, Ford AR. The effect of digoxin on red blood cell function and its relationship to the therapeutic response. In: Tillement J, editor. *Advances in pharmacology and therapeutics. Volume 7, Biochemical clinical pharmacology*. Oxford: Pergamon Press, 1978: 15-22
7. Aronson JK. An aide-memoire for the construction and assessment of clinical trials. *Oxf Med Sch Gaz* 1979; 31: 22-3

8. Aronson JK. Cardiac glycosides and drugs used in dysrhythmias. In: Dukes MNG, editor. *Side Effects of Drugs, Annual 3*. Amsterdam: Excerpta Medica, 1979: Chapter 17A
9. Aronson JK. Cardiac glycosides and drugs used in dysrhythmias. In: Dukes MNG, editor. *Side Effects of Drugs, Annual 4*. Amsterdam: Excerpta Medica, 1980: Chapter 18
10. Aronson JK. Clinical pharmacokinetics of digoxin. *Clin Pharmacokin* 1980; 5(2): 137-49. [PMID: 6988136]
11. Aronson JK. Techniques for studying the pharmacodynamic effects of cardiac glycosides on patients' own tissues during glycoside therapy. In: Rietbrock N, Woodcock BG, Neuhaus G, editors. *Methods in clinical pharmacology*. Braunschweig/Wiesbaden: Vieweg, 1980: 17-25
12. Aronson JK. The effects of digoxin on red cell digitalis receptor function in man. In: *Proceedings of the First World Conference on Clinical Pharmacology and Therapeutics*. London: Macmillan, 1980: 135-44
13. Aronson JK, Grahame-Smith DG. Adverse drug interactions. *Br Med J (Clin Res Ed)* 1981; 282(6260): 288-91. [PMID: 6779990] [Reprinted in *Today's Treatment/4*, London: BMA, 1981.]
14. Aronson JK. Cardiac glycosides and drugs used in dysrhythmias. In: Dukes MNG, editor. *Side Effects of Drugs, Annual 5*. Amsterdam: Excerpta Medica, 1981: Chapter 18
15. Aronson JK. Digoxin: clinical aspects. In: Richens A, Marks V, editors. *Therapeutic drug monitoring*. London and Edinburgh: Churchill Livingstone, 1981: Chapter 17A
16. Aronson JK. Is digitalis useful in clinical practice? *Oxford Medical School Gazette* 1981; 32: 8-9
17. Aronson JK. The interpretation of bradycardia in patients in digitalized patients. *Pract Cardiol* 1981; 7: 114-21
18. Aronson JK, Ford AR, Grahame-Smith DG. Techniques for studying the pharmacodynamic effects of cardiac glycosides on patients' tissues during glycoside therapy. *Klin Wochenschr* 1981; 59(24): 1323-32. [PMID: 6275162]
19. Aronson JK. Cardiac glycosides and drugs used in dysrhythmias. In: Dukes MNG, editor. *Side Effects of Drugs, Annual 6*. Amsterdam: Excerpta Medica, 1982: Chapter 18
20. Aronson JK. Clinical pharmacokinetics of cardiac glycosides in patients with renal dysfunction. *Clin Pharmacokin* 1983; 8(2): 155-78. [PMID: 6342898]
21. Aronson JK. Prevention and detection of adverse drug interactions. *Presc J* 1983; 23: 66-75
22. Aronson JK. Cardiac glycosides and drugs used in dysrhythmias. In: Dukes MNG, editor. *Side Effects of Drugs, Annual 7*. Amsterdam: Excerpta Medica, 1983: Chapter 18
23. Aronson JK. Indications for the measurement of plasma digoxin concentrations. *Drugs* 1983; 26(3): 230-42. [PMID: 6352238] [Reprinted in *New Ethicals* 1984; 21: 123-39.]
24. Green AR, Aronson JK. The pharmacokinetics of oral L-tryptophan: effects of dose and of concomitant pyridoxine, allopurinol or nicotinamide administration. In: Van Praag H, Mendlewicz J, editors. *Management of depression with monoamine precursors*. *Adv Biol Psychiatry* 1984; 10: 67-81
25. Aronson JK. Digitalis. In: Sleight P, Jones JV, editors. *Scientific foundations of cardiology*. London: Heinemann, 1984. Chapter 64
26. Aronson JK. Factors predisposing to digitalis toxicity. *Pract Cardiol* 1984; 10: 49-59
27. Aronson JK. Cardiac glycosides and drugs used in dysrhythmias. In: Dukes MNG, editor. *Side Effects of Drugs, Annual 8*. Amsterdam: Elsevier, 1984: Chapter 18
28. Aronson JK. Receptors and their relevance to drug therapy. *Med Int* 1984; 2: 281-5
29. Aronson JK. Cardiac glycosides and drugs used in dysrhythmias. In: Dukes MNG, editor. *Meyler's side effects of drugs*. 10th edition. Amsterdam: Elsevier, 1984: Chapter 18
30. Aronson JK. Digitalis. In: Parnham MJ, Bruinvels J editors. *Discoveries in pharmacology*. Amsterdam: Elsevier, 1984: Part 3, Chapter 3
31. Aronson JK. The role of the Na⁺,K⁺-ATPase in the regulation of vascular smooth-muscle contractility, and its relationship to essential hypertension. *Trans Biochem Soc* 1984; 12(6): 943-5. [PMID: 6099292]
32. Aronson JK. Cardiac glycosides and drugs used in dysrhythmias. In: Dukes MNG, editor. *Side Effects of Drugs, Annual 9*. Amsterdam: Elsevier, 1985: Chapter 18
33. Aronson JK. Digoxin. *Contemp Issues Clin Biochem* 1985; 3: 182-210. [PMID: 3915966]
34. Aronson JK. Self-poisoning. In: Kennedy HJ, editor. *Emergencies in clinical medicine*. Oxford: Blackwell, 1985: Chapter 31
35. Aronson JK. The clinical, haemodynamic, and pharmacological consequences of digoxin withdrawal after long-term treatment in patients with heart failure in sinus rhythm. In: Erdmann E, Greef KB, Skou JC, editors. *Cardiac glycosides 1785-1985*. Darmstadt: Steinkopff, 1986: 531-3
36. Aronson JK. Cardiac glycosides and drugs used in dysrhythmias. In: Dukes MNG, editor. *Side Effects of Drugs, Annual 10*. Amsterdam: Elsevier, 1986: Chapter 18

37. Hardman M, Aronson JK. Drugs for heart failure. Update 1986; 207-18
38. Aronson JK. Pharmacological terms. Receptors, agonists and antagonists. *Presc J* 1986; 26: 163-5
39. Aronson JK. Digitalis. In: Weatherall DJ, Ledingham JGG, Warrell D, editors. *Oxford textbook of medicine*. Oxford: Oxford University Press, 1987: 13.101-5
40. Aronson JK. Digitalis intoxication and its treatment. *Top Circ* 1987; 2: 9-12
41. Aronson JK. Cardiac glycosides and drugs used in dysrhythmias. In: Dukes MNG, Beeley L, editors. *Side Effects of Drugs, Annual 11*. Amsterdam: Elsevier, 1987. Chapter 18
42. Aronson JK. Interactions that matter: antiarrhythmic drugs. *Presc J* 1987; 27: 27-31
43. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Dukes MNG, Beeley L, editors. *Side Effects of Drugs, Annual 12*. Amsterdam: Elsevier, 1988. Chapter 18
44. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Dukes MNG, editor. *Meyler's side effects of drugs*. 11th edition. Amsterdam: Elsevier, 1988: Chapter 18
45. Aronson JK. Receptors and their relevance to drug therapy. *Medicine* 1988; 59: 2429-34. [Reprinted in *Br J Pharm Pract* 1989; 11: 372-8.]
46. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Dukes MNG, Beeley L, editors. *Side Effects of Drugs, Annual 13*. Amsterdam: Elsevier, 1989: Chapter 18
47. Aronson JK. The treatment of self-poisoning. *Emerg Med Serv* 1989; 18: 51-60
48. Aronson JK. Chronopharmacology: reflections on time and a new text. *Lancet* 1990; 335(8704): 1515-6
49. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Dukes MNG, Beeley L, editors. *Side Effects of Drugs, Annual 14*. Amsterdam: Elsevier, 1990. Chapter 18
50. Aronson JK. Routes of drug administration: 1. Rectal. *Presc J* 1991; 31: 91-7
51. Aronson JK. Routes of drug administration: 2. Sublingual and buccal. *Presc J* 1991; 31: 169-74
52. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Dukes MNG, Aronson JK, editors. *Side Effects of Drugs, Annual 15*. Amsterdam: Elsevier, 1991. Chapter 18
53. Aronson JK. Potassium channels in nervous tissue. *Biochem Pharmacol* 1992; 43(1): 11-14. [PMID: 1734896]
54. Aronson JK. Routes of drug administration: 3. Dermal. *Presc J* 1992; 32: 35-40
55. Aronson JK. Changes in the clinical pharmacology of drugs with age. In: Newman R, editor. *Orthogeriatrics*. London: Butterworth Heinemann, 1992. Chapter 4
56. Aronson JK, Grahame-Smith DG. Adverse reactions to drugs. In: McGee JO'D, Isaacson PG, Wright NA, editors. *Oxford textbook of pathology*. Oxford: Oxford University Press, 1992. Volume 1, Chapter 10: 746-59
57. Aronson JK. Pharmacokinetics for the prescriber. *Med Int* 1992; 101: 4221-8
58. Reynolds DJM, Aronson JK. Selected side-effects: 8. Anaphylactoid reactions to intravenous vitamin K. *Presc J* 1992; 32: 167-70
59. Aronson JK, Hardman M. ABC of monitoring drug therapy. Why monitor drug therapy? *BMJ* 1992; 305(6859): 947-8. [PMID: 1458079]
60. Aronson JK, Hardman M. ABC of monitoring drug therapy. Patient compliance. *BMJ* 1992; 305(6860): 1009-11. [PMID: 1458110]
61. Aronson JK, Hardman M. ABC of monitoring drug therapy. Measuring plasma drug concentrations. *BMJ* 1992; 305(6861): 1078-80. [PMID: 1467691]
62. Aronson JK, Hardman M. ABC of monitoring drug therapy. Digoxin. *BMJ* 1992; 305(6862): 1149-52. [PMID: 1463955]
63. Aronson JK, Hardman M, Reynolds DJM. ABC of monitoring drug therapy. Phenytoin. *BMJ* 1992; 305(6863): 1215-18. [PMID: 1467727]
64. Aronson JK, Reynolds DJM. ABC of monitoring drug therapy. Lithium. *BMJ* 1992; 305(6864): 1273-6. [PMID: 1477574]
65. Aronson JK, Hardman M, Reynolds DJM. ABC of monitoring drug therapy. Theophylline. *BMJ* 1992; 305(6865): 1355-8. [PMID: 1483087]
66. Aronson JK, Reynolds DJM. ABC of monitoring drug therapy. Aminoglycoside antibiotics. *BMJ* 1992; 305(6866): 1421-4. [PMID: 1486311]
67. Reynolds DJM, Aronson JK. ABC of monitoring drug therapy. Cyclosporin. *BMJ* 1992; 305(6867): 1491-4. [PMID: 1493401]
68. Aronson JK. The principles of prescribing in renal failure. *Presc J* 1992; 32: 220-31
69. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Dukes MNG, editor. *Meyler's side effects of drugs*. 12th edition. Amsterdam: Elsevier, 1992: Chapter 18
70. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Dukes MNG, Aronson JK, editors. *Side Effects of Drugs, Annual 16*. Amsterdam: Elsevier, 1992. Chapter 18

71. Reynolds DJM, Aronson JK. ABC of monitoring drug therapy. Making the most of plasma drug concentration measurements. *BMJ* 1993; 306(6869): 48-51. [PMID: 8435581]
72. Peto TEA, Aronson JK. Zidovudine. *Presc J* 1993; 32: 124-9
73. Aronson JK. Drug absorption: achieving optimal clinical response. *Prescriber* 1993; 4(8): 77-80
74. Aronson JK. Drug excretion: what the prescriber should know. *Prescriber* 1993; 4(16): 31-4
75. Aronson JK. How drugs produce their pharmacological effects. *Prescriber* 1993; 4(19): 21-5
76. Aronson JK. Drug action via enzymes and transport systems. *Prescriber* 1993; 4(20): 64-8
77. Aronson JK. Routes of drug administration: 4. Inhalation. *Presc J* 1993; 32: 164-9
78. Aronson JK. Serious drug interactions. *Practitioner* 1993; 237: 789-91. [PMID: 7903448]
79. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, Van Boxtel CJ, editors. *Side Effects of Drugs, Annual 17*. Amsterdam: Elsevier, 1993. Chapter 18
80. Aronson JK. How the activity and numbers of sodium/potassium pumps in human lymphocytes are regulated. In: Haunsø S, Kjeldsen K, editors. *Proceedings of the XV European Section Meeting of the International Society for Heart Research, Copenhagen*. Bologna: Monduzzi Editore, 1994; 231-8
81. Aronson JK. Beneficial drug interactions. *Practitioner* 1994; 238(1540): 514-8. [PMID: 7937504]
82. Aronson JK. Anti-infective drugs. In: Walton J, Barondess J, Lock S, editors. *New Oxford medical companion*. Oxford: OUP, 1994; 41-6
83. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, Van Boxtel CJ, editors. *Side Effects of Drugs, Annual 18*. Amsterdam: Elsevier, 1995. Chapter 18
84. Aronson JK. Local anesthetics. In: Aronson JK, Van Boxtel CJ, editors. *Side Effects of Drugs, Annual 18*. Amsterdam: Elsevier, 1995. Chapter 12
85. Aronson JK. Routes of drug administration: 5. Intramuscular. *Presc J* 1995; 35: 32-6
86. Aronson JK, White NJ. Principles of clinical pharmacology and drug therapy. In: Weatherall DJ, Ledingham JGG, Warrell D, editors. *Oxford textbook of medicine, 3rd edition*. Oxford: Oxford University Press, 1995: 1235-63
87. Aronson JK. Confusion over similar drug names. Problems and solutions. *Drug Saf* 1995; 12(3): 155-60. [PMID: 7619327]
88. Aronson JK. How to choose an antibiotic. In: *The Medical Book*. London: Medilink Press, 1995/6: 37-8
89. Aronson JK. Advantages and pitfalls of surrogate markers. In: Collier JG, editor. *Proceedings of the Fourth Drug and Therapeutics Bulletin symposium. From trial outcomes to clinical practice*. London: Which? Ltd, 1996: 5-10
90. Aronson JK. Local anesthetics. In: Aronson JK, Van Boxtel CJ, editors. *Side Effects of Drugs, Annual 19*. Amsterdam: Elsevier, 1996. Chapter 11
91. Leuwer M, Zuzan O, Aronson JK. Neuromuscular blocking agents and skeletal muscle relaxants. In: Aronson JK, Van Boxtel CJ, editors. *Side Effects of Drugs, Annual 19*. Amsterdam: Elsevier, 1996. Chapter 12
92. Aronson JK. Cardiac glycosides and drugs used in dysrhythmias. In: Aronson JK, Van Boxtel CJ, editors. *Side Effects of Drugs, Annual 19*. Amsterdam: Elsevier, 1996. Chapter 17
93. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Dukes MNG, editor. *Meyler's side effects of drugs, 13th edition*. Amsterdam: Elsevier, 1996: Chapter 17
94. Aronson JK. General anesthetics and therapeutic gases. In: Aronson JK, editor. *Side Effects of Drugs, Annual 20*. Amsterdam: Elsevier, 1997. Chapter 10
95. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, editor. *Side Effects of Drugs, Annual 20*. Amsterdam: Elsevier, 1997. Chapter 17
96. Aronson JK. Antifungal drugs. In: Aronson JK, editor. *Side Effects of Drugs, Annual 20*. Amsterdam: Elsevier, 1997. Chapter 27
97. Aronson JK. Prescribing in renal insufficiency: principles and practice. In: Jamison RL, Wilkinson R, editors. *Nephrology*. London: Chapman & Hall, 1997. Chapter 69
98. Aronson JK. Routes of drug administration: 7. Subcutaneous administration. *Presc J* 1998; 38: 50-5 (correspondence 195-6)
99. Aronson JK, Derry S. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, editor. *Side Effects of Drugs, Annual 21*. Amsterdam: Elsevier, 1998. Chapter 17
100. Aronson JK, Proudfoot AT. Principles of drug therapy and management of poisoning. In: C Haslett, ER Chilvers, JAA Hunter, NA Boon, editors. *Davidson's principles and practice of medicine, 18th edition*. Edinburgh: Churchill Livingstone, 1999. Chapter 19
101. Aronson JK. Drugs and renal insufficiency. *Med Int* 1999; 27(7): 113-18
102. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, editor. *Side Effects of Drugs, Annual 22*. Amsterdam: Elsevier, 1999. Chapter 17

103. Aronson JK. Miscellaneous antibacterial drugs. In: Aronson JK, editor. *Side Effects of Drugs, Annual 22*. Amsterdam: Elsevier, 1999. Chapter 26
104. Aronson JK. Drug absorption: achieving optimal clinical response. *Prescriber* 1999; 10(17): 45-54
105. Aronson JK. Drug excretion: what the prescriber should know. *Prescriber* 1999; 10(20): 67-75
106. Aronson JK. How drugs produce their pharmacological effects: 1. *Prescriber* 1999; 10(22): 19-26
107. Aronson JK. How drugs produce their pharmacological effects: 2. *Prescriber* 1999; 10(23): 60-5
108. Edwards IR, Aronson JK. Adverse drug reactions—definitions, classification, diagnosis, management, surveillance. *Lancet* 2000; 356(9237): 1255-60. [PMID: 11072960]
109. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, editor. *Side Effects of Drugs, Annual 23*. Amsterdam: Elsevier, 2000. Chapter 17
110. Aronson JK. General principles of drug therapy. In: *Oxford textbook of psychiatry*. Oxford: Oxford University Press, 2000; Chapter 6.2.1: 1275-84
111. Aronson JK. Neurological side-effects of drugs: an overview. *Prescriber* 2001; 12(5): 43-8
112. Richards DB, Aronson JK. Pharmacological terms used in advertisements for antihypertensive drugs: what information do they give us? *Modern Hypertension Management* 2001; 3: 9-14
113. Aronson JK. Antiepileptic drugs. In: Aronson JK, editor. *Side Effects of Drugs, Annual 25*. Amsterdam: Elsevier, 2001. Chapter 7
114. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, editor. *Side Effects of Drugs, Annual 25*. Amsterdam: Elsevier, 2002. Chapter 17
115. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, editor. *Side Effects of Drugs, Annual 25*. Amsterdam: Elsevier, 2002. Chapter 17
116. Aronson JK. Anti-infective drugs. In: S Lock, JM Last, G Dunea, editors. *The Oxford Illustrated Companion to Medicine*. Third Edition. Oxford: OUP, 2002
117. Aronson JK. Placebos. In: S Lock, JM Last, G Dunea, editors. *The Oxford Illustrated Companion to Medicine*. Third Edition. Oxford: OUP, 2002
118. Aronson JK. Drug therapy. In: Haslett C, Chilvers ER, Boon NA, Colledge NR, editors., Hunter JAA, international editor. *Davidson's Principles and Practice of Medicine*, 19th edition. Edinburgh: Elsevier Science Limited, 2002: 147-63
119. Aronson JK. Plant poisons. In: G Cook, A Zumla, editors. *Manson's Tropical Diseases*, 21st edition. London: Harcourt International, 2002; Chapter 26
120. Maxwell S, Walley T; BPS Clinical Section Committee. Teaching safe and effective prescribing in UK medical schools: a core curriculum for tomorrow's doctors. *Br J Clin Pharmacol* 2003; 55(6): 496-503. [PMID: 12814441]
121. Aronson JK. Drugs and renal insufficiency. *Med Int* 2003; 31(7): 103-9
122. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, editor. *Side Effects of Drugs, Annual 26*. Amsterdam: Elsevier, 2003. Chapter 17
123. Aronson JK. Heart failure. In: DJ Weatherall, D Warrell, J Firth, editors. *Oxford textbook of medicine*. Oxford: Oxford University Press, 2003; 2: 959-68
124. Aronson JK. Drugs and renal insufficiency. *Surgery* 2003; 21: 104a-104f
125. Aronson JK. Medication errors resulting from the confusion of drug names. *Expert Opin Drug Saf* 2004; 3(3): 167-72. [PMID: 15155145]
126. Aronson JK. Adverse drug reactions: an introduction. *Hosp Pharm Europe* 2004; 13 Mar/Apr
127. Aronson JK. Neurological adverse drug reactions. *Hosp Pharm Europe* 2004; 15 Jul/Aug
128. Aronson JK. Louis Lewin—Meyler's predecessor. In: Aronson JK (editor). *Side Effects of Drugs Annual 27*. Amsterdam: Elsevier, 2004: xxv-xxix
129. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, editor. *Side Effects of Drugs, Annual 27*. Amsterdam: Elsevier, 2004. Chapter 17
130. Aronson JK. Adjusting therapeutic dosage regimens to optimise the balance of benefit to harm. *Clin Med* 2005; 5(1): 16-19. [PMID: 15745191]
131. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, editor. *Side Effects of Drugs, Annual 28*. Amsterdam: Elsevier, 2005. Chapter 17
132. Keeling DM, Aronson JK. Drugs affecting blood coagulation, fibrinolysis, and hemostasis. In: Aronson JK, editor. *Side Effects of Drugs, Annual 28*. Amsterdam: Elsevier, 2005. Chapter 35
133. Choulis NH, Aronson JK. Miscellaneous drugs and materials, medical devices, and techniques. In: Aronson JK, editor. *Side Effects of Drugs, Annual 28*. Amsterdam: Elsevier, 2005. Chapter 49
134. Aronson JK. Drug therapy. In: Boon NA, Colledge NR Walker BR, editors., Hunter JAA, international editor. *Davidson's Principles and Practice of Medicine*, 20th edition. Edinburgh: Churchill Livingstone, 2006: 17-35

135. Aronson JK. Drugs and renal insufficiency. *The Foundation Years* 2006; 3(1): 7-13. doi.org/10.1016/j.mpfou.2006.11.003
136. Aronson JK. Industry-sponsored clinical research—an editor's view. In: Halkin H, Tal O, editors. *Patients, Physicians, and Pharma*. Haifa: The Israel National Institute for Health Policy Research, 2006: 15-28
137. Aronson JK. Meyler's—cornerstone of the pharmacovigilance library. *Uppsala Reports* 2007; Jan: 21
138. Aronson JK. Drugs and renal insufficiency. *Medicine* 2007; 35(7): 396-8. pmmed.2007.04.013
139. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, editor. *Side Effects of Drugs, Annual 29*. Amsterdam: Elsevier, 2007. Chapter 17; doi 10.1016/S0378-6080(06)29017-2
140. Choulis NH, Aronson JK. Miscellaneous drugs and materials, medical devices, and techniques. In: Aronson JK, editor. *Side Effects of Drugs, Annual 29*. Amsterdam: Elsevier, 2007. Chapter 49; doi 10.1016/S0378-6080(06)29049-4
141. Aronson JK. General principles of drug therapy in psychiatry. In: *Oxford textbook of psychiatry*. Oxford: Oxford University Press, 2008; Chapter 6.2.1
142. Glasziou P, Aronson JK. An introduction to monitoring therapeutic interventions in clinical practice. In: Glasziou P, Irwig L, Aronson JK, editors. *Evidence-based Medical Monitoring: From Principles to Practice*. Oxford: Blackwell Publishing/BMJ Books, 2008: 3-14
143. Aronson JK, Michie S. Developing monitoring tools: integrating the pathophysiology of disease and the mechanisms of action of therapeutic interventions. In: Glasziou P, Irwig L, Aronson JK, editors. *Evidence-based Medical Monitoring: From Principles to Practice*. Oxford: Blackwell Publishing/BMJ Books, 2008: 31-47
144. Aronson JK. Biomarkers and surrogate endpoints in monitoring therapeutic interventions. In: Glasziou P, Irwig L, Aronson JK, editors. *Evidence-based Medical Monitoring: From Principles to Practice*. Oxford: Blackwell Publishing/BMJ Books, 2008: 48-62
145. Coleman JJ, Ferner RE, Aronson JK. Monitoring for the adverse effects of drugs. In: Glasziou P, Irwig L, Aronson JK, editors. *Evidence-based Medical Monitoring: From Principles to Practice*. Oxford: Blackwell Publishing/BMJ Books, 2008: 194-210
146. Goosens AE, Aronson JK. Dermatological drugs, topical agents, and cosmetics. In: Aronson JK, editor. *Side Effects of Drugs, Annual 30*. Amsterdam: Elsevier, 2008. Chapter 14; doi 10.1016/S0378-6080(08)00014-7
147. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, editor. *Side Effects of Drugs, Annual 30*. Amsterdam: Elsevier, 2008. Chapter 17; doi 10.1016/S0378-6080(08)00017-2
148. Aronson JK. Medication errors. In: Aronson JK, editor. *Side Effects of Drugs, Annual 30*. Amsterdam: Elsevier, 2008. Chapter 50; doi 10.1016/S0378-6080(08)00063-9
149. Aronson JK. Plant poisons. In: G Cook, A Zumla, editors. *Manson's Tropical Diseases*, 22nd edition. London: Harcourt International, 2009; Chapter 32: 601-26
150. Aronson JK. Routes of drug administration: uses and adverse effects. Part 1: Intramuscular and subcutaneous injection. *Adv Drug React Bull* 2009; (253): 971-4
151. Aronson JK. Routes of drug administration: uses and adverse effects. Part 2: Sublingual, buccal, rectal, and some other routes. *Adv Drug React Bull* 2009; (254): 975-8
152. Aronson JK. Medication errors: what they are, how they happen, and how to avoid them. *QJM* 2009; 102(8): 513-21. [PMID: 19458202]
153. Aronson JK. Medication errors: definitions and classification. *Br J Clin Pharmacol* 2009; 67(6): 599-604. [PMID: 19594526]
154. Aronson JK. Anti-inflammatory and antipyretic analgesics and drugs used in gout. In: Aronson JK, editor. *Side Effects of Drugs Annual 31*. Chapter 9. Amsterdam: Elsevier Science, 2009: 181-215; doi 10.1016/S0378-6080(09)03101-8
155. Aronson JK. Drugs that affect autonomic functions or the extrapyramidal system. In: Aronson JK, editor. *Side Effects of Drugs Annual 31*. Chapter 13. Amsterdam: Elsevier Science, 2009: 259-85; doi 10.1016/S0378-6080(08)03115-8
156. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, editor. *Side Effects of Drugs Annual 31*. Chapter 17. Amsterdam: Elsevier Science, 2009: 321-38; doi 10.1016/S0378-6080(09)03117-1
157. Aronson JK. Diuretics. In: Aronson JK, editor. *Side Effects of Drugs Annual 31*. Chapter 21. Amsterdam: Elsevier Science, 2009: 371-81; doi 10.1016/S0378-6080(09)03121-3
158. Aronson JK. Antifungal drugs. In: Aronson JK, editor. *Side Effects of Drugs Annual 31*. Chapter 27. Amsterdam: Elsevier Science, 2009: 457-67; doi 10.1016/S0378-6080(09)03127-4

159. Aronson JK. Patent medicines and secret remedies. *BMJ* 2009; 339: b5415. [PMID: 20008435]
160. Aronson JK. Clinical pharmacology and therapeutics in the UK—a great instauration. *Br J Clin Pharmacol* 2010; 69(2): 111-7. [PMID: 20233173]
161. Aronson JK. Therapeutics and good prescribing. In: Colledge NR Walker BR, Ralston SH, editors. *Davidson's Principles and Practice of Medicine*. 21st edition. Edinburgh: Churchill Livingstone, 2010: Chapter 2
162. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, editor. *Side Effects of Drugs Annual 32*. Chapter 17. Amsterdam: Elsevier Science, 2010: 333-62; doi 10.1016/S0378-6080(10)32017-4
163. Aronson JK. Drugs that affect blood coagulation, fibrinolysis, and hemostasis. In: Aronson JK, editor. *Side Effects of Drugs Annual 32*. Chapter 35. Amsterdam: Elsevier Science, 2010: 617-63; doi 10.1016/S0378-6080(10)32035-6
164. Aronson JK. Drugs that affect lipid metabolism. In: Aronson JK, editor. *Side Effects of Drugs Annual 32*. Chapter 44. Amsterdam: Elsevier Science, 2010: 803-26; doi 10.1016/S0378-6080(10)32044-7
165. Aronson JK. Radiological contrast agents. In: Aronson JK, editor. *Side Effects of Drugs Annual 32*. Chapter 46. Amsterdam: Elsevier Science, 2010: 843-64; doi 10.1016/S0378-6080(10)32046-0
166. Aronson JK. Medication errors. In: Aronson JK, editor. *Side Effects of Drugs Annual 32*. Chapter 50. Amsterdam: Elsevier Science, 2010: 903-22; doi 10.1016/S0378-6080(10)32050-2
167. Ferner RE, Aronson JK. Pharmacogenetics and adverse drug reactions. *Adv Drug React Bull* 2010; (264): 1015-8
168. Aronson JK. Diuretics. In: Aronson JK, editor. *Side Effects of Drugs Annual 33*. Chapter 21. Amsterdam: Elsevier Science, 2011: 437-45; doi: 10.1016/B978-0-444-53741-6.00021-0
169. Lartey M, Torpey K, Aronson JK. Antiviral drugs. In: Aronson JK, editor. *Side Effects of Drugs Annual 33*. Chapter 29. Amsterdam: Elsevier Science, 2011: 577-621; doi: 10.1016/B978-0-444-53741-6.00029-5
170. Allwood MC, Aronson JK. Vitamins, intravenous solutions, and drugs and formulations used in nutrition. In: Aronson JK, editor. *Side Effects of Drugs Annual 33*. Chapter 34. Amsterdam: Elsevier Science, 2011: 691-706; doi: 10.1016/B978-0-444-53741-6.00034-9
171. Aronson JK. Drugs that affect blood coagulation, fibrinolysis, and hemostasis. In: Aronson JK, editor. *Side Effects of Drugs Annual 33*. Chapter 35. Amsterdam: Elsevier Science, 2011: 707-39; doi: 10.1016/B978-0-444-53741-6.00035-0
172. Aronson JK. Drugs that act on the immune system: immunosuppressive and immunostimulatory drugs. In: Aronson JK, editor. *Side Effects of Drugs Annual 33*. Chapter 38. Amsterdam: Elsevier Science, 2011: 815-39; doi: 10.1016/B978-0-444-53741-6.00038-6
173. Aronson JK. Adverse drug reactions: history, terminology, classification, causality, frequency, preventability. In: Talbot J, Aronson JK, editors. *Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice*. 6th edition. Oxford: Wiley-Blackwell, 2011: 1-119
174. Raine J, Wise L, Talbot J, Aronson JK. Proactive pharmacovigilance and risk management. In: Talbot J, Aronson JK, editors. *Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice*. 6th edition. Oxford: Wiley-Blackwell, 2011: 389-409
175. Barker CIS, Talbot J, Aronson JK. Web sites relevant to pharmacovigilance—an analysis of contents. In: Talbot J, Aronson JK, editors. *Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice*. 6th edition. Oxford: Wiley-Blackwell, 2011: 685-97
176. Aronson JK. Guidelines and a checklist for reporting suspected adverse drug reactions anecdotally in journals. In: Talbot J, Aronson JK, editors. *Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice*. 6th edition. Oxford: Wiley-Blackwell, 2011: 699-708
177. Aronson JK. Evaluation of pharmacological evidence for forensic purposes. *Int J Risk Saf Med* 2012; 24(1): 3-12. doi 10.3233/JRS-2012-0547. [PMID:22436254]
178. Aronson JK. An agenda for UK clinical pharmacology: Research priorities in biomarkers and surrogate endpoints. *Br J Clin Pharmacol* 2012; 73(6): 900-7. doi: 10.1111/j.1365-2125.2012.04234.x. [PMID:22360291]
179. Buclin T, Gotta V, Fuchs A, Widmer N, Aronson JK. An agenda for UK clinical pharmacology: Monitoring drug therapy. *Br J Clin Pharmacol* 2012; 73(6): 917-23. doi: 10.1111/j.1365-2125.2012.04237.x. [PMID:22360377]
180. Green AR, Aronson JK. An agenda for UK clinical pharmacology: from basic to clinical neuropharmacology—targetophilia or pharmacodynamics? *Br J Clin Pharmacol* 2012; 73(6): 959-67. doi: 10.1111/j.1365-2125.2012.04246.x. [PMID:22360689]
181. Aronson JK. Balanced prescribing—principles and challenges. *Br J Clin Pharmacol* 2012; 74(4): 566-72. doi: 10.1111/j.1365-2125.2012.04413.x. [PMID: 22950551]

182. Aronson JK. Drugs that affect autonomic functions or the extrapyramidal system. In: Aronson JK, editor. *Side Effects of Drugs Annual 34*. Chapter 13. Amsterdam: Elsevier Science, 2012: 233-255; <http://dx.doi.org/10.1016/B978-0-444-59499-0.00001-5>
183. Aronson JK. Metals. In: Aronson JK, editor. *Side Effects of Drugs Annual 34*. Chapter 22. Amsterdam: Elsevier Science, 2012: 349-66; <http://dx.doi.org/10.1016/B978-0-444-59499-0.00001-5>
184. Aronson JK. Penicillins, cephalosporins, other beta-lactam antibiotics, and tetracyclines. In: Aronson JK, editor. *Side Effects of Drugs Annual 34*. Chapter 25. Amsterdam: Elsevier Science, 2012: 385-97; <http://dx.doi.org/10.1016/B978-0-444-59499-0.00001-5>
185. Aronson JK. Antifungal drugs. In: Aronson JK, editor. *Side Effects of Drugs Annual 34*. Chapter 27. Amsterdam: Elsevier Science, 2012: 427-39; <http://dx.doi.org/10.1016/B978-0-444-59499-0.00001-5>
186. Aronson JK. Vitamins, intravenous solutions, and drugs and formulations used in nutrition. In: Aronson JK, editor. *Side Effects of Drugs Annual 34*. Chapter 34. Amsterdam: Elsevier Science, 2012: 531-39; <http://dx.doi.org/10.1016/B978-0-444-59499-0.00001-5>
187. Swales CL, Aronson JK. Medication and health in the workplace. In: Palmer KT, Brown I, Hobson J (editors). *Fitness for Work*. 5th edition. Oxford: OUP, 2013: 507-24
188. Aronson J, Jackson S, Pirmohamed M, Ritter J. Clinical pharmacology and therapeutics. In: Royal College of Physicians. *Consultant Physicians Working with Patients*. Revised 5th edition (online update). London: RCP, 2013: 73-80
189. Aronson JK. Plant poisons and traditional medicines. In: Farrar J, Hotez PJ, Junghanss T, Kang G, Lalloo DG, White NJ, editors. *Manson's Tropical Diseases*, 23rd edition. London: Harcourt International, 2014; Chapter 76
190. Aronson JK. Antipsychotic drugs. In: Aronson JK, editor. *Side Effects of Drugs Annual 35*. Chapter 6. Amsterdam: Elsevier Science, 2014: 85-131; <http://dx.doi.org/10.1016/B978-0-444-62635-6.00006-1>
191. Aronson JK. Opioid analgesics and narcotic antagonists. In: Aronson JK, editor. *Side Effects of Drugs Annual 35*. Chapter 8. Amsterdam: Elsevier Science, 2014: 171-95; <http://dx.doi.org/10.1016/B978-0-444-62635-6.00006-1>
192. Aronson JK. Antiseptic drugs and disinfectants. In: Aronson JK, editor. *Side Effects of Drugs Annual 35*. Chapter 24. Amsterdam: Elsevier Science, 2014: 435-45; <http://dx.doi.org/10.1016/B978-0-444-62635-6.00006-1>
193. Onakpoya I, Aronson JK. Vitamins, intravenous solutions, and drugs and formulations used in nutrition. In: Aronson JK, editor. *Side Effects of Drugs Annual 35*. Chapter 34. Amsterdam: Elsevier Science, 2014: 607-15; <http://dx.doi.org/10.1016/B978-0-444-62635-6.00006-1>
194. Masclee G, Aronson JK. Drugs that act on the immune system: cytokines and monoclonal antibodies. In: Aronson JK, editor. *Side Effects of Drugs Annual 35*. Chapter 37. Amsterdam: Elsevier Science, 2014: 659-97; <http://dx.doi.org/10.1016/B978-0-444-62635-6.00006-1>
195. Gales L, Aronson JK. Thyroid hormones, iodine and iodides, and antithyroid drugs. In: Aronson JK, editor. *Side Effects of Drugs Annual 35*. Chapter 41. Amsterdam: Elsevier Science, 2014: 747-61; <http://dx.doi.org/10.1016/B978-0-444-62635-6.00006-1>
196. Aronson JK. Cytostatic and cytotoxic drugs. In: Aronson JK, editor. *Side Effects of Drugs Annual 35*. Chapter 45. Amsterdam: Elsevier Science, 2014: 821-61; <http://dx.doi.org/10.1016/B978-0-444-62635-6.00006-1>
197. Ferner RE, Mackenzie AA, Aronson JK. The adverse effects of nitrous oxide. *Adv Drug React Bull* 2014; 285: 1099-102
198. Aronson JK. Case reports as evidence in pharmacovigilance. In: Mann's *Pharmacovigilance*. 3rd edition. Oxford: Wiley-Blackwell, 2014: Chapter 10: 121-37
199. Aronson JK. The management of pain during injection of propofol. *Adv Drug React Bull* 2014; (287): 1107-10
200. Aronson JK. Photosensitivity reactions and skin tumours associated with voriconazole. *Adv Drug React Bull* 2015; 290: 1119-22
201. Aronson JK. How a VOICE for clinical pharmacology turns into a RECIPE for its development. *Transl Clin Pharmacol* 2016; 24(1): 1-6

F Presentations to national and international learned societies; letters to journals; other occasional pieces

1. Aronson JK, Arthur F, Grahame-Smith DG, Hallis KF. Monitoring digoxin therapy: the use of erythrocytic ⁸⁶rubidium uptake. *Br J Clin Pharmacol* 1975; 2(2): 187-8P. [PMCID: PMC1402511]
2. Grahame-Smith DG, Aronson JK, Boullin DJ, Orr M. Proceedings: Cellular biochemical pharmacology in monitoring drug therapy. *Arzneimittelforschung* 1976; 26(6): 1256-7. [PMID: 989454]
3. Aronson JK, Ford AR. The use of quantitative colour vision testing in diagnosing digitalis toxicity. Presented to the 7th International Congress of Pharmacology, Paris, 1978
4. Grahame-Smith DG, Aronson JK, Ford AR. The effect of digoxin therapy on red blood cell function and its relationship to the therapeutic response. In: Proceedings of the 7th International Congress of Pharmacology, Paris, 1978
5. Royer RJ, Zannad F, Robert J, Royer MJ, Grahame-Smith DG, Aronson JK. Monitoring digoxin therapy: comparison between tissue response and clinical effects. Presented to the 7th International Congress of Pharmacology, Paris 1978
6. Aronson JK, Ford AR, Grahame-Smith DG. The pharmacological effects of digoxin which occur during the short-term treatment do not persist in the long-term. *QJM* 1979; NS48: 644
7. Aronson JK. The effects of digoxin on red cell digitalis receptor function in man. Presented to the First World Conference on Clinical Pharmacology and Therapeutics, London, 1980
8. Green AR, Aronson JK. The metabolism of oral L-tryptophan. Presented to the First World Conference on Clinical Pharmacology and Therapeutics, London, 1980
9. Willoughby CP, Aronson JK, Agback H, Bodin NO, Anderson E, Truelove SC. Disposition in normal volunteers of sodium diazosalicylate, a potential therapeutic agent in inflammatory bowel disease. *Gut* 1981; 22: A431
10. Aronson JK, Carver JG. Interaction of digoxin with quinine. *Lancet* 1981; 1(8235): 1418. [PMID: 6113370]
11. Pugh SE, White NJ, Aronson JK, Grahame-Smith DG, Carver JG. Erythrocytic digoxin receptor numbers and activity: relation to clinical changes following digoxin withdrawal after long-term treatment for heart failure in sinus rhythm. *Br J Clin Pharmacol* 1982; 13(2): 271-2P. [PMCID: PMC1401983]
12. Aronson JK, Grahame-Smith DG, Hallis KF, White NJ. The effect of digoxin on the in vivo disposition of an oral load of rubidium chloride. *Br J Clin Pharmacol* 1982; 13(4): 606-7P. [PMCID: PMC1402046]
13. Boon NA, Hallis KF, Aronson JK, Pugh S, Conway J, Grahame-Smith DG. The disposition of oral rubidium chloride in essential hypertension. *Clin Sci (Lond)* 1982; 63(3): 68P-69P
14. Boon N, Aronson JK. Sodium efflux and essential hypertension. *Lancet* 1982; 2(8308): 1160. [PMID: 6128474]
15. Aronson JK, Moore MP, Redman CW, Harper C. Sodium-lithium countertransport in erythrocytes of pregnant women. *N Engl J Med* 1982; 307(26): 1645-6. [PMID: 7144857]
16. Boon NA, Oh VMS, Taylor EA, Johansen T, Aronson JK, Grahame-Smith DG. [³H]-ouabain binding and ⁸⁶rubidium uptake in polymorphonuclear and mononuclear leucocytes. *Br J Clin Pharmacol* 1983; 15(5): 617P. [PMCID: PMC1427722]
17. Oh VMS, Taylor EA, Boon NA, Aronson JK, Grahame-Smith DG. Stimulation of [³H]-ouabain binding to intact human lymphocytes by normal human and fetal calf serum. *Br J Clin Pharmacol* 1983; 15(5): 618P. [PMCID: PMC1427722]
18. Aronson JK, Carver JG. Diagnosing digoxin toxicity by combined measurement of plasma digoxin concentrations and erythrocytic ⁸⁶rubidium uptake. *Br J Clin Pharmacol* 1983; 15(5): 618-9P. [PMCID: PMC1427722]
19. Boon NA, Rose JA, Hallis KF, Jones JV, Manley BS, Aronson JK. Evidence that cation transport is reduced in vivo in one-kidney one clip hypertension. Presented to the First European Meeting on Hypertension, Milan, 1983
20. Aronson JK, Boon NA, Hallis KF, Pugh SE, Grahame-Smith DG. In vivo disposition on oral rubidium: effect of short-term and long-term digoxin. Presented to the Second World Conference on Clinical Pharmacology and Therapeutics, Washington DC, 1983
21. Boon NA, Raine AE, Hallis KF, Perkins CM, Grahame-Smith DG, Aronson JK. In vivo evidence of reduced cation transport in chronic renal failure. *Clin Sci (Lond)* 1983; 65(3): 60P
22. Boon NA, Pugh SE, Hallis KF, Aronson JK, Grahame-Smith DG. Evidence that cation transport in vivo is inhibited by short-term but not long-term digoxin therapy. *Br Heart J* 1984; 51: 690
23. Rapeport WG, Aronson JK, Grahame-Smith DG, Harper C. The effects of lithium, ethacrynic acid, and low potassium on specific lymphocyte [³H]-ouabain binding. *Br J Clin Pharmacol* 1985; 20(3): 259P. [PMCID: PMC1400698]
24. Rapeport WG, Aronson JK, Grahame-Smith DG, Harper C. Increased specific [³H]-ouabain binding to lymphocytes after incubation with acetylstrophanthidin for 3 days. *Br J Clin Pharmacol* 1985; 20(3): 277-8P. [PMCID: PMC1400698]

25. Hardman M, Viswalingam A, Priddle JD, Aronson JK, Grahame-Smith DG. Partial purification and characterization of an endogenous inhibitor of Na,K-ATPase. Presented to the Third World Conference on Clinical Pharmacology and Therapeutics, Stockholm, 1986
26. Wood AJ, Viswalingham A, Aronson JK, Grahame-Smith DG. The effect of lithium on cation transport in vivo and in vitro in healthy volunteers. *Br J Clin Pharmacol* 1987; 23(5): 609-10P. [PMCID: PMC1386199]
27. Kennedy DG, Bloomfield JG, Aronson JK, Grahame-Smith DG. The effect of a low external potassium concentration on the Na/K-ATPase of human lymphoblasts. *Br J Clin Pharmacol* 1987; 23(5): 639P. [PMCID: PMC1386199]
28. Wood AJ, Aronson JK, Cowen PJ, Grahame-Smith DG. In vivo measurement of cation transport in patients suffering from acute manic illness. Presented to a conference on New Directions in Affective Disorder, Jerusalem, 1987
29. Wood AJ, Brearley CJ, Aronson JK, Grahame-Smith DG. The effects of salbutamol on in vivo cation transport. *Br J Clin Pharmacol* 1988; 25(5): 624-5P. [PMCID: PMC1386439]
30. Brearley CJ, Wood AJ, Aronson JK, Grahame-Smith DG. The in vivo disposition of lithium in patients with untreated essential hypertension. *Clin Sci (Lond)* 1988; 75(s19): 55P
31. Syme PD, Allis JL, Dixon RM, Aronson JK, Grahame-Smith DG, Radda GK. Quantification of rubidium concentrations in rat muscle in vivo using high resolution nuclear magnetic resonance spectroscopy. Presented to the Seventh Annual Meeting of the Society of Magnetic Resonance in Medicine, San Francisco 1988
32. Jenkins RJ, Aronson JK. The effects of lithium on Na/K pump numbers and activity in isolated human lymphocytes in vitro. *Br J Clin Pharmacol* 1989; 27(5): 654-5P. [PMCID: PMC1379936]
33. Moraes, MEA de, Aronson JK, Grahame-Smith DG. The pharmacokinetics of intravenous stable strontium in healthy volunteers. *Br J Clin Pharmacol* 1989; 27(5): 673-4P. [PMCID: PMC1379936]
34. Moraes, MEA de, Aronson JK, Grahame-Smith DG. The effect of the calcium antagonist nifedipine on the disposition of strontium after the intravenous infusion of stable strontium gluconate. *QJM* 1989; NS73: 971-2
35. Brearley CJ, Wood AJ, Aronson JK, Grahame-Smith DG. In vivo measurement of the rate and stoichiometry of sodium/sodium countertransport in human erythrocytes and the effects of essential hypertension. *QJM* 1989; NS73: 972-3
36. Jenkins RJ, Ng LL, Aronson JK. Increased intracellular pH and Na/H exchange in lymphocytes exposed to lithium for 72 h. *Eur J Clin Pharmacol* 1989; 36: A91
37. Syme PD, Dixon RM, Aronson JK, Grahame-Smith DG, Radda GK. Evidence for increased in vivo Na⁺/K⁺-ATPase activity in skeletal muscle of spontaneously hypertensive rats. *Clin Sci (Lond)* 1990; 78(s22): 8P
38. Syme PD, Arnolda L, Green Y, Aronson JK, Grahame-Smith DG, Radda GK. Evidence for increased in vivo Na⁺/H⁺ antiporter activity in skeletal muscle of spontaneously hypertensive rats. *Clin Sci (Lond)* 1990; 78(s22): 8P
39. Syme PD, Arnolda L, Green Y, Aronson JK, Radda GK. Evidence for increased Na⁺/H⁺ antiporter activity in skeletal muscle of spontaneously hypertensive rats, measured by NMR spectroscopy. Presented to the 13th scientific meeting of the International Society of Hypertension, 1990
40. Syme PD, Arnolda L, Green Y, Aronson JK, Radda GK. Altered contractile response in skeletal muscle of spontaneously hypertensive rats in association with increased in vivo Na⁺/H⁺ antiporter activity. Presented to the 13th scientific meeting of the International Society of Hypertension, 1990
41. Ameen M, Bloomfield J, Aronson JK. The effects of a low extracellular concentration of potassium for 72 h on Na/K pump numbers and activity in human lymphoblasts and their reversal within 24 h. *Br J Pharmacol (Proc Suppl)* 1990; 100: 470P
42. Syme P, Arnolda L, Aronson JK, Radda GK. Increased Na⁺-H⁺ antiport activity in vivo in skeletal muscle of spontaneously hypertensive rats can be reversed by nifedipine. *J Hypertens* 1990; 8: 1064-5
43. Aronson JK, Jenkins RJ, Ng LL. Regulation of the activity of the Na/K-ATPase —the effect of lithium and the mechanism of its action. *Trace Elements Med* 1990; 7: 94-5
44. Wood AJ, Smith CE, Clarke EE, Cowen PJ, Aronson JK, Grahame-Smith DG. Altered adaptive responses of the lymphocyte Na⁺,K⁺-ATPase in bipolar affective illness. *Biol Psychiatry* 1991; 29: 318S
45. Ameen M, Peek AR, Aronson JK, Lamb JF. The cellular distribution of Na/K pumps in human lymphoblasts after exposure to a low extracellular concentration of potassium. *Br J Pharmacol (Proc Suppl)* 1992; 105: 207P
46. Ameen M, Aronson JK, Lamb JF. Long term effects of growth in low K medium on sodium pump activity in human cultured cells. *J Physiol (Lond)* 1993; 459: 43P

47. Aronson JK, Reynolds DJM. Monitoring lithium treatment: Authors' reply. *BMJ* 1993; 306(6872): 270. [PMCID: PMC1676716]
48. Aronson JK, Reynolds DJM. Monitoring theophylline treatment: Authors' reply. *BMJ* 1993; 306(6875): 457. [PMCID: PMC1676551]
49. Aronson JK, Reynolds DJM. Monitoring treatment with aminoglycoside antibiotics: Authors' reply. *BMJ* 1993; 306(6874): 392-3. [PMCID: PMC1676433]
50. Vanags DM, Bloomfield J, Aronson JK, Grahame-Smith DG. Pharmacological characterization of potassium channels on human platelets. Presented to the Sixth International Symposium on Pharmacological Control of Calcium and Potassium Homeostasis, Florence 1994
51. Smith CC, Bennett PM, Pearce HM, Reynolds DJ, Aronson JK, Grahame-Smith DG. NSAIDs and gut toxicity. *Lancet* 1994; 344(8914): 56-7. [PMID: 7912318]
52. Murton RA, Aronson JK. Upregulation of sodium/potassium pumps by the loop diuretic ethacrynic acid—possible role of phosphoinositide turnover. *Br J Pharmacol Proc Suppl* 1995; 114: 240P
53. Murton RA, Aronson JK. Upregulation of Na/K pumps by loop diuretics—non-involvement of Na/K/2Cl co-transport. *Br J Pharmacol Proc Suppl* 1995; 116: 154P
54. De Silva HA, Carver JG, Aronson JK. Stimulation of potassium (⁸⁶Rubidium) efflux from human platelets by external potassium and its inhibition by bumetanide—evidence for Na/K/Cl co-transport. *Br J Pharmacol Proc Suppl* 1996; 117: 115P
55. De Silva HA, Carver JG, Aronson JK. Calcium-activated and ATP-dependent potassium channels in human platelets. *Br J Pharmacol Proc Suppl* 1996; 118: 102P
56. De Silva HA, Aronson JK. Evidence for calcium-dependent (K_{Ca}) and voltage-dependent (K_v) potassium channels in human platelets. *Pharmacologist* 1997; 39: 57
57. Aronson JK, De Silva HA. Evidence for potassium/chloride co-transporters in human platelets. *Pharmacologist* 1997; 39: 59
58. Murton RA, Aronson JK. Upregulation of Na/K pumps by ethacrynic acid: role of altered phosphoinositide (PI) hydrolysis. *Pharmacologist* 1997; 39: 63
59. De Silva HA, Aronson JK. Interaction between the Na⁺/K⁺/2Cl⁻ co-transporters in human platelets. *Br J Pharmacol Proc Suppl* 1997; 122: 92P
60. Aronson JK. Digoxin revisited. *QJM* 1998; 91(10): 713. [PMID: 10024931]
61. Mendes Ribeiro AC, Brunini TMC, Aronson JK, Ellory JC, Mann GE. L-arginine transport in human platelets is mediated by the high affinity amino acid transport system y⁺L. *J Physiol (Lond)* 1999; 517: 26P
62. John NG, Aronson JK. Effects of homocysteine on potassium channels in human platelets. *Br J Pharmacol Proc Suppl* 1999; 128: 253P
63. Brunini TMC, Ashman N, Yaqoob M, Aronson JK, Ellory JC, Mann GE, Mendes Ribeiro AC. Homocysteine inhibition of system y⁺L in human platelets: implications for atherosclerosis in uraemia. *J Physiol* 2000; 523: 76P-77P
64. Thomas J, Phipps S, Aronson JK. Effects of homocysteine, cysteine, and methionine on charybdotoxin-sensitive potassium channels in human platelets. *Proc West Pharmacol Soc* 2001
65. Richards DBJ, Aronson JK. Stimulation of cation flux in human platelets by physiological concentrations of angiotensin: possible relevance to monitoring of the actions of ACE inhibitors. *Proc West Pharmacol Soc* 2001
66. Ferner RE, Aronson JK. Adverse events in British hospitals. Retrospective case record analysis has been superseded. *BMJ* 2001; 322(7299): 1427. [PMID: 11417562]
67. de Silva HA, Fonseka MMD, Pathmeswaran A, Ratnatilake GA, Alahakoon DGS, Ranasingha CD, Gunatilake SB, Laloo DG, Aronson JK, de Silva HJ. Treatment of yellow oleander poisoning with multiple-dose activated charcoal: a randomized placebo-controlled trial. *Br J Clin Pharmacol* 2003; 55(4): 422-3. [PMCID: PMC1884242]
68. Aronson JK, Derry S, Loke YK. Assessing perceptions of benefit and harm of common drug therapies using therapeutic scenarios. *Br J Clin Pharmacol* 2003; 55(4): 438. [PMCID: PMC1884242]
69. de Silva HA, Aronson JK, Ranasinghe C, Gunatilake SB, de Silva HJ. Multidose activated charcoal for yellow oleander poisoning - Authors' reply. *Lancet* 2003; 362(9383): 581
70. Odontiadis J, Franklin M, Powell J, Attenburrow MH, Aronson J, Cowen PJ. Changes in plasma tryptophan following a naturally enhanced source: a pharmacokinetic study. *J Psychopharmacol* 2003; 17: A16
71. Hauben M, Aronson JK. Gold standards in pharmacovigilance: the use of definitive anecdotal adverse drug reactions as pure gold and high grade ore. *Drug Saf* 2006; 29(10): 989
72. Hauben M, Aronson JK. Paradoxical reactions: under-recognized adverse effects of drugs. *Drug Saf* 2006; 29(10): 1022

73. Aronson JK, Barnett DB, Ferner RE, Ferro A, Henderson G, Maxwell SR, Rawlins MD, Webb DJ. Poor prescribing is continual. *BMJ* 2006; 333(7571): 756. [PMID: 17023482]
74. Aronson JK, Hauben M. Between-the eyes adverse drug reactions. *Cochrane Colloquium*, Dublin 2006
75. Aronson JK. Glomerular filtration rate: eGFR in changing drug regimens. *BMJ* 2007; 334(7607): 1287. [PMID: 17585126]
76. Aronson J. Female pseudonyms. *Times Lit Suppl* 2007; 2 Mar; 17
77. de Silva HA, Pathmeswaran A, Laloo DG, de Silva HJ, Aronson JK. Multiple-dose activated charcoal in yellow oleander poisoning. *Lancet* 2008; 371(9631): 2171. [PMID: 18586169]
78. Aronson JK. Observational evidence for determining drug safety: too high a pedestal. *BMJ* 2008; 336(7647): 735. [PMID: 18390501]
79. Aronson JK. Publishing histories of adverse reactions to medicaments anecdotally: the PHARMA guidelines for reporting suspected adverse drug reactions. *Drug Saf* 2008; 31(4): 355-6. [PMID: 18366246]
80. Aronson JK. Message from the President. *pA₂* 2008; 6(1): 3-4
81. Aronson JK. The pharmacological network. *Pharmacol Matters* 2008; 1(2): 6-7
82. Aronson JK, Barnett DB, Breckenridge AM, Ferner RE, Jackson P, Maxwell SR, McInnes GT, Rawlins MD, Ritter JM, Routledge P, Walley TJ, Webb DJ, Williams D, Woods KL. The UK's NHS and pharma: need for more clinical pharmacologists. *Lancet* 2009; 373(9671): 1251-2. [PMID: 19362673]
83. Aronson JK. Increasing access to medicines. Time for category of pharmacist consultation and supply. *BMJ* 2009; 338: b1899. doi: 10.1136/bmj.b1899. [PMID: 19435767]
84. Aronson JK. Balanced prescribing and the information that we need to achieve it. *Basic Clin Pharmacol Toxicol* 2009; 105 (Suppl 1): 3-4
85. Hughes DA, Aronson JK. A systematic review and empirical analysis of the relation between dose and duration of drug action. *Basic Clin Pharmacol Toxicol* 2009; 105 (Suppl 1): 32
86. De Silva HA, Ranasinha CD, Pathmeswaran A, Laloo D, Armitage J, Aronson JK, De Silva HJ. Prevention of acute adverse reactions to antivenom in snakebite: interim report of blinded data from a randomised, controlled trial. *BPS Summer Meeting 2009: 081P*. pA₂ online. <http://www.a2online.org/abstract/abstract.jsp?abid=29403&author=De%20Silva&cat=1&period=42>
87. Aronson JK. Pharmacologists in the Oxford Dictionary of National Biography. *Pharmacol Matters* 2009; 2(1): 24-5
88. Aronson JK. A great instauration. *Pharmacol Matters* 2009; 2(3): 4-7
89. Aronson JK. CPT or huliatics? *Pharmacol Matters* 2009; 2(3): 22-3
90. Aronson JK. A model for academic clinicians. *Pharmacol Matters* 2009; 2(3): 24-5
91. Weetman T, Aronson J, Maxwell S. Reducing prescription errors. *Lancet* 2010; 375(9713): 461-2. [PMID: 20152541]
92. Aronson JK, Maxwell S. Preparedness of Foundation Year doctors to prescribe. *Postgrad Med J* 4 Dec 2008. http://pmj.bmj.com/content/85/1009/582/reply#postgradmedj_el_5474
93. Aronson JK. A manifesto for clinical pharmacology. *Pharmacol Matters* 2010; 3(1): 35-8
94. Aronson JK. Found in translation: human pharmacology comes of age. *Basic Clin Pharmacol Toxicol* 2010; 107 (Suppl 1): 693
95. Li N, Aronson J. The test dose—how to be a more valuable and reliable predictor? *Basic Clin Pharmacol Toxicol* 2010; 107 (Suppl 1): 411
96. Aronson JK, Ferner RE. Length of treatment. Three questions for prescribers. *BMJ* 2010; 341: c5013. doi: 10.1136/bmj.c5013. [PMID: 20843922]
97. Aronson JK. Integrating pharmacology and clinical pharmacology. *Br J Clin Pharmacol* 2011; 71(5): 787-90
98. Barker CIS, Aronson JK. National pharmacovigilance websites: clarity and communication. *Br J Clin Pharmacol* 2011; 71(6): 986
99. Barker CIS, Aronson JK. Sialadenitis due to iodinated contrast media ('iodide mumps')—evidence for two separate mechanisms. *Basic Clin Pharmacol Toxicol* 2011; 109 Suppl 1: 87
100. Aronson J, Barker C. Enhancing the exposure of UK undergraduate medical students to Clinical Pharmacology and Therapeutics: a proposed UK-wide Special Study Module. *Pharmacol Matters* 2011; 4(2): 9-11
101. Ramachandran M, Aronson JK. Authors' response to Hasan. *J R Soc Med* 2011; 104(9): 350. [PMID: 21881083]
102. Iessa N, Star K, Wilton L, Curran S, Edwards IR, Aronson JK, Murray M, Besag FM, Wong IC. Montelukast and suicide: causality assessment using spontaneous reports and Bradford Hill guidelines. *Drug Saf* 2011; 34(10): 949-50
103. Aronson JK. David Grahame-Smith. *BMJ* 2011; 343: d6378. doi: 10.1136/bmj.d6378

104. Aronson JK. David Grahame Grahame-Smith: Clinical pharmacologist 1933–2011. *Br J Clin Pharmacol* 2011 Dec 6. doi: 10.1111/j.1365-2125.2011.04160.x. [PMID: 22142441]
105. Aronson JK. System rather than target driven approach needed to discover beneficial drug effects. *BMJ* 2012; 344: e543. doi: 10.1136/bmj.e543. [PMID:22275412]
106. Aronson JK. Surrogate end points: studying their benefits, taxonomy, and semantics. *BMJ* 2012; 344: e750. doi: 10.1136/bmj.e750. [PMID:22293384]
107. Vazquez-Montes MV, Stevens RJ, Oke J, Aronson JK, Farmer AJ. HbA_{1c} before and after starting treatment with metformin in a large diabetes type 2 cohort. *Diabetologia* 2012; 55(Suppl 1): S325
108. Floor-Schreudering A, Geerts AF, Aronson JK, Bouvy ML, Ferner RE, Smet PAGMD. Towards improved drug-drug interaction management guidelines. European Society of Clinical Pharmacy, 41st Symposium, Barcelona, Spain. 29-31 October 2012: ESCP12-1432. *Int J Clin Pharm* 2013; 35(5): 904-5
109. Iessa N, Star K, Murray ML, Wilton L, Curran S, Edwards IR, Aronson JK, Besag F, Wong ICK. An evaluation of the evidence of an association between montelukast and suicide: a publicity exacerbated signal? *Drug Saf* 2012; 35(10): 901
110. Aronson JK. Self-experimentation and the Nobel Prize. *Pharmacol Matters* 2012; 5(Dec): 5-6
111. Aronson JK. Shakespeare's medicine cabinet. *Pharmacol Matters* 2013; August: 22-3
112. Onakpoya I, Heneghan C, Aronson JK. Drug withdrawals because of deaths after marketing: a systematic review. *Proc Br Pharmacol Soc*. <http://www.pA2online.org/abstracts/Vol11Issue2abst013P.pdf>
113. Aronson JK. Great American novels. *Times Lit Suppl* 2014; Aug 1: 6
114. Aronson JK. David Grahame Grahame-Smith. *Oxford Dict Nat Biog* 2014
115. Aronson JK. Remembering Eric Korn. *Times Lit Suppl* 2015; Jan 30: 6
116. Onakpoya IJ, Heneghan CJ, Aronson JK. Post-approval withdrawal of medicines because of adverse drug reactions: a systematic review. *Clin Ther* 2015; 37(8): e30
117. Onakpoya I, Heneghan C, Aronson J. Post-marketing withdrawal of medicines because of adverse drug reactions: an analysis of antiobesity medications. *Drug Saf* 2015; 38(10): 1016-7
118. Aronson JK. Do mechanisms constitute clinical evidence? Presented to the MuST9 workshop, "Evidence, Inference, and Risk", Munich, 31 March to 2 April 2016
119. O'Sullivan JW, Aronson J. Practices of no net benefit. *BMJ Open* 2016;6:4 e010723. http://bmjopen.bmj.com/content/6/4/e010723.full/reply#bmjopen_el_9707

G Medical language

Articles on medical words in the BMJ, under the general heading "When I Use a Word ..."

- | | |
|-----------------------------------------------------------|-----------------------------------------------------------------------|
| 1. Curious, yellow. 1996; 312(7022): 28 | 19. Buyers and sellers. 1997; 315(7106): 483 |
| 2. Wine and roses. 1996; 312(7024): 178 | 20. Sausages. 1997; 315(7108): 599 |
| 3. Here's mud in your eye. 1996; 312(7027): 373 | 21. Wool gathering. 1997; 315(7112): 840 |
| 4. Who was Fuller? 1996; 313(7056): 534 | 22. Fingerprints. 1997; 315(7113): 930 |
| 5. Old chestnuts. 1996; 313(7058): 670 | 23. Crosses and stars. 1997; 315(7123): 1658 |
| 6. Regime, regimen, regiment. 1996; 313(7058): 673 | 24. What's my name? 1998; 316(7125): 124 |
| 7. H ₂ ≠ H ₂ . 1996; 313(7061): 873 | 25. Spurious words. 1998; 316(7130): 534 |
| 8. Ae, ae, ae! 1996; 313(7066): 1201 | 26. Medical Greek. 1998; 316(7134): 845. [PMCID: PMC1112774] |
| 9. Hiccup. 1996; 313(7068): 1326 | 27. Fillers. 1998; 316(7149): 1990. [PMCID: PMC1113435] |
| 10. Got an ology? 1997; 314(7073): 28 | 28. Protean elephants. 1998; 317(7150): 89. [PMID: 9651302] |
| 11. Shalom Salmonella. 1997; 314(7073): 49 | 29. The venereal game. 1998; 317(7157): 535. [PMCID: PMC1113761] |
| 12. A time to be born. 1997; 314(7085): 973 | 30. Grapes. 1998; 317(7159): 688. [PMCID: PMC1113857] |
| 13. Sloe gin. 1997; 314(7087): 1106 | 31. Homogenous/homogeneous. 1999; 318(7180): 376. [PMCID: PMC1114842] |
| 14. Fortysomething. 1997; 314(7095): 1674 | 32. Please, please me. 1999; 318(7185): 716. [PMCID: PMC1115150] |
| 15. Difficult pronunciation. 1997; 315(7100): 107 | |
| 16. Quacks. 1997; 315(7101): 165 | |
| 17. Oe no! 1997; 315(7102): 225 | |
| 18. Hippopotamonstrorsesquipedalian. 1997; 315(7103): 292 | |

33. Hepatojugular reflux. 1999; 318(7192): 1172. [PMCID: PMC1115583]
34. X marks the spot. 1999; 318(7197): 1543. [PMCID: PMC1115907]
35. Oranges and grapefruit. 1999; 318(7200): 1758. [PMCID: PMC1116091]
36. Allergy and immunity. 1999; 319(7205): 308. [PMCID: PMC1126941]
37. Now concentrate. 1999; 319(7208): 494. [PMCID: PMC1116388]
38. That's show business. 1999; 319(7215): 972. [PMCID: PMC1116803]
39. Fin de siècle countdown. 1999; 319(7225): 1595. [PMCID: PMC1127082]
40. Modern English Abusage. 2000; 320(7231): 357. [PMCID: PMC1127144]
41. Overate? 2000; 320(7235): 625. [PMCID: PMC1117655]
42. NICE? 2000; 320(7237): 749
43. Cheque your spelling. 2000; 320(7240): 990. [PMID: 10753156]
44. Monthly injections. 2000; 320(7241): 1071. [PMID: 10764374]
45. Say cee. 2001; 321(7261): 611. [PMID: 10977841]
46. Chickenpox. 2001; 321(7262): 682. [PMID: 10987775]
47. An/atomy. 2001; 321(7266): 953. [PMID: 11030692]
48. A medical alphabet. 2001; 321(7276): 1598. [PMID: 11124194]
49. The last word. 2001; 322(7289): 782. [PMCID: PMC1119958]
50. Oh? Why? 2001; 322(7292): 967. [PMCID: PMC1120136]
51. Re: re-. 2001; 322(7295): 1166. [PMCID: PMC1120287]
52. -ize right. 2001; 323(7322): 1173. [PMCID: PMC1121647]
53. A Christmas quiz. 2001; 323(7327): 1497. [PMCID: PMC1121919]
54. Terrorist. 2002; 324(7333): 355. [PMCID: PMC1122275]
55. Medicalization. 2002; 324(7342): 904. [PMCID: PMC1122839]
56. Round the back. 2002; 324(7343): 957. [PMCID: PMC1122903]
57. Meta-. 2002; 324(7344): 1022. [PMCID: PMC1122956]
58. Masses and masses. 2002; 324(7352): 1521. [PMCID: PMC1123453]
59. Ough ough. 2002; 325(7356): 160. [PMCID: PMC1123679]
60. When I use a mocking bird. 2002; 325(7358): 245. [PMCID: PMC1123773]
61. Patient centred verbs. 2002; 325(7360): 387. [PMCID: PMC1123893]
62. Man hater. 2003; 326(7382): 216. [PMCID: PMC1125069]
63. Wholly, holy, holey. 2003; 326(7385): 392. [PMCID: PMC1125246]
64. Dropsy. 2003; 326(7387): 491. [PMCID: PMC1125373]
65. The eyes have it. 2003; 326(7390): 639. [PMCID: PMC1125537]
66. Anecdoteage. 2003; 327(7426): 1276. [PMCID: PMC286252]
67. HARMful reactions. 2004; 328(7449): 1173. [PMCID: PMC411096]
68. Balancing benefits and harms in health care. 2004; 329(7456): 30. [PMCID: PMC443449]
69. Medical emoticons. 2005; 330(7482): 87. [PMCID: PMC543876]
70. Faux amis. 2005; 330(7498): 1006. [PMCID: PMC557151]
71. Rabid responses. 2005; 331(7513): 383. [PMCID: PMC1184250]
72. Bottled lightning. 2005; 331(7520): 824. [PMCID: PMC1246084]
73. Incestuous sheets. 2005; 331(7529): 1378. [PMCID: PMC1309647]
74. The very last word. 2006; 332(7540): 535. [PMCID: PMC1388135]
75. Nauseated/nauseous. 2006; 332(7552): 1271. [PMCID: PMC1471970]
76. Rare diseases, orphan drugs, and orphan diseases. 2006; 333(7559): 127. [PMCID: PMC1502161]
77. Sometimes, never. 2006; 333(7565): 445. [PMCID: PMC1553544]
78. Consultation. 2006; 333(7571): 737. [PMCID: PMC1592389]
79. The matter with 'issue'. 2006; 333(7577): 1059. [PMCID: PMC1647343]
80. Colourful metals. 2007; 334(7586): 205. [PMCID: PMC1781989]
81. Geographic metals. 2007; 334(7587): 258. [PMCID: PMC1790748]
82. No effect. 2007; 334(7593): 578. [PMCID: PMC1828314]
83. Words that count. 2007; 334(7603): 1104. [PMCID: PMC1877929]
84. Tom Swifties. 2008; 337: a836
85. Spitting images. 2010; 340: b5064
86. Formularies and pharmacopoeias. 2011; 342: d34
87. Found in translation. 2011; 342: 2762
88. Twice blessed. 2011; 343: d6281
89. Lickerish liquorice. 2012; 344: e1453
90. Hard data, soft data. 2012; 344: e1692
91. "Well tolerated" is intolerable 2014; 349: g5385
92. Five types of skepticism 2015; 350: h1986
93. Safety 2015; 351: h3521
94. Good prescribing: benefits, hazards, harms, and risks. 2016; 352: i537.

Articles in the Quarterly Journal of Medicine, under the general heading "When I Use a Word ..."

1. Ordinary words with extraordinary meanings. 2008; 101(12): 993-4
2. Words misheard—medical mondegreens. 2009; 102(4): 301-2. [Epub 2009 Jan 21] [PMID: 19158157]
3. Fulsomely banning 'compendious'. 2009; 102(7): 509-10.[Epub 2009 Apr 8] [PMID: 19359252]
4. Is it inflammation? It is! 2009; 102(12): 895-6. [Epub 2009 Apr 15] [PMID: 19369482]
5. Changing your practice. 2010; 103(1): 63-5. [Epub 2009 May 21] [PMID: 19465373]
6. Declarative titles. 2010; 103(3): 207-9. [Epub 2009 Jun 29] [PMID: 19564241]
7. Materia medica, clinical pharmacology, and therapeutics. 2010; 103(5): 361-3. [Epub 2009 Jul 22] [PMID: 19625349]
8. Sex, gender, and segeny. QJM 2011; 104(7): 633-5. [Epub 2011 Jan 11] [PMID: 21224328]
9. Misunderspellings. QJM 2011; 104(12): 1109-10. [Epub 2011 Aug 24] [PMID: 21865310]
10. Innovations—"The Births of Time". QJM 2012; 105(10): 1037-9. [Epub 2012 Jun 11] [PMID:22690008]

Other word articles (see also J. Blogs)

1. Aronson JK. "Where name and image meet"—the argument for "adrenaline" BMJ 2000; 320: 506-9. [PMID: 10678871]
2. Aronson JK. Francis Galton and the invention of terms for quantiles. J Clin Epidemiol 2001; 54: 1191-4. [PMID: 11750187]
3. Aronson JK. Disco dancing. Cytopathology 2002; 13(5): 326-7. [PMID: 12421449]
4. Aronson JK. When I Use a Word ... Mabs. Br J Gen Pract 2004; 54(504): 559. [PMCID: PMC1324822]
5. Aronson JK. When I Use a Word ... Goitre/goiter. Rev Argent Endocrinol Metab 2013
6. Aronson JK. Medical eponyms: taxonomies, natural history, and the evidence. BMJ 2014; 349: g7586

H Medical humanities

1. Aronson JK. Medicine in Staffordshire. Br Med J 1977; 1(6067): 1031-2. [PMID: 322810]
2. Aronson JK. An Account of the Foxglove and its Medical Uses 1785-1985. Oxford: Oxford University Press, 1985 [incorporating a facsimile of William Withering's monograph An account of the foxglove ... (1785) in a specially annotated edition]. ISBN 0-19-261501-7. [Spanish translation by D Mario Petit Guinovart & Juan Hernández Herrero, 1988.]
3. Aronson JK. The discovery of the foxglove as a therapeutic agent. Chem Brit 1987; 23: 33-6
4. Aronson JK. Coloured vision? New Scientist 1990; 30 June: 80-1
5. Aronson JK. Classics in clinical pharmacology and therapeutics. Penicillin. Eur J Clin Pharmacol 1992; 42(1): 1-9. [PMID: 1541305] [Also at www.jameslindlibrary.org]
6. Aronson JK. Drugs—their history. Streptomycin. Med Int 1993; 21(6): vi-vii
7. Aronson JK. Drugs—their history. Lithium. Med Int 1993; 21(7): vi
8. Aronson JK. Drugs—their history. Methotrexate. Med Int 1993; 21(9): v-vi
9. Aronson JK. A brief defence of curiosity. Oxf Mag 1994; 111: 3-4
10. Aronson JK. Green College and the history of medicine. Green Coll Rec 1999: 11-13
11. Aronson JK. Autopathography—the patient's tale. BMJ 2000; 321(7276): 1599-1602. [PMID: 11124195]
12. Aronson JK. John Coakley Lettsom and the introduction of digitalis into clinical practice at the end of the eighteenth century. Trans Med Soc Lond 2002-3; 119: 77-85. [PMID: 17184033]
13. Aronson JK. Signs of love, not a love potion. [Commentary on Weitz G. Love and death in Wagner's *Tristan und Isolde*. —an epic anticholinergic crisis.] BMJ 2003; 327(7429): 1471-2. [PMID: 14684653]
14. Aronson JK. Louis Lewin—Meyler's predecessor. In: Aronson JK, editor. Side Effects of Drugs, Annual 27. Amsterdam: Elsevier, 2005: xxv-xxix
15. Aronson JK. Wiliam Osler. The teacher with open arms. Oxford Today 2005; 17(3): 17
16. Ramachandran M, Aronson JK. The diagnosis of art: arthrogryposis and Ribera's *The Clubfoot*. J R Soc Med 2006; 99(6): 321-2. [PMID: 16821292]
17. Aronson JK, Ramachandran M. The diagnosis of art: melancholy and the *Portrait of Dr Gachet*. J R Soc Med 2006; 99(7): 373-4. [PMID: 22135838] [reprinted in Meditheme 2006; 25: 92-5]
18. Aronson JK, Ramachandran M. The diagnosis of art: exophthalmos—Gustave Doré's ogre. J R Soc Med 2006; 99(8): 421. [PMID: 16981319]

19. Ramachandran M, Aronson JK. The diagnosis of art: Rachmaninov's hand span. *J R Soc Med* 2006; 99(10): 529-30. [PMID: 17066567]
20. Ramachandran M, Aronson JK. The diagnosis of art: diastrophic dysplasia and Hephaistos. *J R Soc Med* 2006; 99(11): 584-5. [PMID: 22135839]
21. Ramachandran M, Aronson JK. The diagnosis of art: Lowry's gallery of cripples. *J R Soc Med* 2007; 100(3): 153-4. [PMID: 22135840]
22. Aronson JK, Ramachandran M. The diagnosis of art: Valentin le désossé and Ehlers–Danlos syndrome. *J R Soc Med* 2007; 100(4): 193-4. [PMID: 17563952]
23. Ramachandran M, Aronson JK. The diagnosis of art: Achilles Empeire and spondyloepiphyseal dysplasia congenita. *J R Soc Med* 2007; 100(8): 384-5. [PMID: 17821829]
24. Aronson JK, Ramachandran M. The diagnosis of art: Caravaggio's jaundiced Bacchus. *J R Soc Med* 2007; 100(9): 429-30. [PMID: 17941166]
25. Aronson JK, Ramachandran M. The diagnosis of art: Alice, the Duchess, Sir John Tenniel, foxgloves, and roses. *J R Soc Med* 2007; 100(12): 576-8. [PMID: 18229434]
26. Ramachandran M, Aronson JK. The diagnosis of art: Albrecht Dürer and the Christ Child's drooped shoulder. *J R Soc Med* 2008; 101(2): 87-8. [PMID: 22135841]
27. Aronson JK, Ramachandran M. The diagnosis of art: Dr Péan's operation. *J R Soc Med* 2008; 101(8): 423-4. [PMID: 18788145]
28. Aronson JK, Ramachandran M. The diagnosis of art: Millais' blind girl. *J R Soc Med* 2008; 101(11): 564-5. [PMID: 22135842]
29. Hughes N, Ramachandran M, Aronson JK. The diagnosis of art: Sir George Savile, 8th Baronet—the ears have it? *J R Soc Med* 2008; 101(12): 605-6. [PMID: 19108339]
30. Aronson JK, Ramachandran M. The diagnosis of art: Van Gogh and male pattern baldness *J R Soc Med* 2009; 102(1): 32-3. [PMID: 19156985]
31. Aronson JK, Ramachandran M. The diagnosis of art: Durer's squint—and Shakespeare's? *J R Soc Med* 2009; 102(9): 391-3. [PMID: 22132457]
32. Aronson JK. Patent medicines and secret remedies. *BMJ* 2009; 339: b5415. [PMID: 20008435]
33. Aronson JK, Ramachandran M. The diagnosis of art: Scleroderma in Paul Klee—and Rembrandt's scholar? *J R Soc Med* 2010; 103(2): 70-1. [PMID: 22141181]
34. Aronson JK, Ramachandran M. The diagnosis of art: Ernst Ludwig Kirchner's 'nervous breakdown'. *J R Soc Med* 2010; 103(3): 112-3. [PMID: 20229643]
35. Aronson JK, Ramachandran M. The diagnosis of art: W H Auden's face. *J R Soc Med* 2011; 104(1): 38-40. [PMID: 22141182]
36. Ramachandran M, Aronson JK. Benjamin Brodie's infamous case of Isambard Kingdom Brunel and an inhaled gold coin. 1843. *J R Soc Med* 2011; 104(4): 149-54. [PMID: 21502213]
37. Ramachandran M, Aronson JK. Frederick Treve's first surgical operation for appendicitis. *J R Soc Med* 2011; 104(5): 191-7. [PMID: 21558097]
38. Ramachandran M, Aronson JK. John Bostock's first description of hayfever. *J R Soc Med* 2011; 104(6): 237-40. doi: 10.1258/jrsm.2010.10k056. [PMID: 21659398]
39. Ramachandran M, Aronson JK. John and James Parkinson's first description of acute appendicitis and its associated complications of perforation and death. *J R Soc Med* 2011; 104(7): 283-5. doi: 10.1258/jrsm.2010.10k057. [PMID: 21725093]
40. Ramachandran M, Aronson JK. The first description of hayfever? Response. *J R Soc Med* 2011; 104(9): 350
41. Ramachandran M, Aronson JK. John Marshall's first description of surgical electrocautery. *J R Soc Med* 2011; 104(9): 355-60. [PMID: 21881086]
42. Ramachandran M, Aronson JK. Jacob Lockhart Clarke's and John Hughlings Jackson's first description of syringomyelia. *J R Soc Med* 2012; 105(2): 60-5. [PMID:22357981]

I Book reviews etc

Many book, CD, radio, and television reviews in learned journals, including the *BMJ*, *Lancet*, *New England Journal of Medicine*, *British Journal of Clinical Pharmacology*, *European Journal of Clinical Pharmacology*, *Neurochemistry International*, *Trends in Biochemical Science*, and *Medical History*, including:

1. Aronson J. *A Textbook of Clinical Pharmacology* [Rodgers H], Spector RG, and Trounce JR; Hodder & Stoughton, 1981]. *Oxf Med School Gaz* 1981; 42-3
2. Aronson JK. *Metal Ions in Neurology and Psychiatry* [Edited by S Gabay, J Harris, and BT Ho. *Neurol Neurobiol* 1985; 15: 409.] *J Neurochem* 1986; 9(4): 564

3. Aronson JK. Medicine and Books. Illustrations that fail to illuminate. [*Atlas of Drug Reactions*. RD Collins. Churchill Livingstone, 1985.] Br Med J (Clin Res Ed) 1986; 293(6554): 1093
4. Aronson JK. *Medical Pharmacology at a Glance*. [MJ Neal. Blackwell Scientific, 1987.] Neurochem Int 1988; 13(3): 415-6
5. Aronson JK. Essential Essays [Review of *Doctors in Science and Society Essays of a Clinical Scientist*. Christopher C. Booth. Cambridge University Press for the Memoir Club, 1987.] Lancet 1987; 330(8563): 849
6. Aronson JK. *Handbook of Renal-Independent Cardiac Glycosides: Pharmacology and Clinical Pharmacology*. Norbert Rietbrock and Barry G. Woodcock. Ellis Horwood, 1989: 334(8672); 1130-1
7. Aronson JK. Chronopharmacology: reflections on time and a new text. [*Chronopharmacology: Cellular and Biochemical Interactions*. Edited by Björn Lemmer. Marcel Dekker, 1989.] Lancet 1990; 335(8704): 1515-6
8. Aronson JK. Rates of exchange. *Sodium-Calcium Exchange*. Edited by TJA Allen, Denis Noble, and Harald Reuter, Oxford University Press, 1989. Trends Biochem Sci 1991; 16: 41
9. Aronson JK. *Clinical Chronopharmacology. Concepts, kinetics, application* [Edited by A. Reinberg; Hemisphere Publishing Corporation, 1990]. Br J Clin Pharmacol 1991; 32(2): 263-4. [PMCID: PMC1368459]
10. Aronson JK. Book Review [*Drugs in old age: new perspectives*. Edited by MJ Denham and CF George.] Eur J Clin Pharmacol 1991; 40(1): 122
11. Aronson JK. *Dictionary of plants containing secondary metabolites* [JS Glasby; Taylor & Francis, 1991]. Eur J Clin Pharmacol 1993; 44(6): 606-7
12. Aronson J. Small World. [Review of *Microcosmographia Academica. Being a Guide for the Young Academic Politician*, by FM Cornford; MainSail Press, 1993.] Oxford Magazine 1994; 105: 17-19.
13. Aronson J. *Exciting Times in the Accounts Department*. [Paul Vaughan; Sinclair-Stevenson, 1994.] BMJ 1995; 311(7012): 1105-6
14. Aronson JK. Crossing the channels. [Review of *Antiarrhythmic Therapy: a Pathophysiologic Approach*, by Members of the Sicilian Gambit, 1994.] Eur J Clin Pharmacol 1995; 48(5): 401-2
15. Aronson JK. *Medical Pharmacology at a Glance* [MJ Neil; Blackwell Science Ltd, 1998] Br J Clin Pharmacol 1998; 46(1): 91-2
16. Aronson J. *Wellcome Witnesses to Twentieth-Century Medicine, vol 1*. Med Hist 1998; 42(3): 404-5
17. Aronson JK. *The Surgeon of Crowthorne: A Tale of Murder, Madness and the Love of Words* [Simon Winchester; Viking, 1998]. BMJ 1998; 317(7163): 957. [PMID: 9756838]
18. Aronson JK. Windows shopping [Review of bookshops on the internet]. BMJ 1999; 318(7194): 1359 [full version at <http://bmj.com/cgi/content/full/318/7194/1359/DC1>]. [PMID: 10323845]
19. Aronson JK. *A Dictionary of Pharmacology and Allied Topics* (2nd edition) [Desmond Laurence, John Carpenter; Elsevier, 1998]. Trends Pharmacol Sci 1999; 20: 125
20. Aronson JK. *Herbal Remedies Heilpflanzen*. Second revised edition [CD ROM; Athomas Brendler, Joerg Gruenwald, Christof Jaenicke; Deutscher Apotheker Verlag, 2000]. Eur J Clin Pharmacol 2000; 56(2): 195-6
21. Aronson JK. *Drug Regimen Compliance. Issues in clinical trials and patient management* [edited by Jean-Michel Metry and Urs A Meyer; John Wiley & Sons Ltd, 1999]. Eur J Clin Pharmacol 2000; 56(2): 196
22. Aronson JK. *Pharmacotherapy: a Pathophysiologic Approach*. N Engl J Med 2000; 342(20): 1535-6
23. Aronson J. *New Labour, New Language?* [Norman Fairclough; Routledge, 1999]. BMJ 2000; 320(7247): 1480. [PMID: 10827065]
24. Aronson JK. Diamond is forever. [Review of *Snake Oil and Other Preoccupations*, by John Diamond; Vintage UK, 2001.] BMJ 2001; 323(7307): 288. [PMCID: PMC1120899]
25. Aronson JK. *The Words of Medicine: Sources, Meanings, and Delights*. BMJ 2001; 323(7316): 813. [PMCID: PMC1121358]
26. Aronson JK CAM-corders. [Review of *Snake Oil* by John Diamond. Vintage, 2001]. Eur J Clin Pharmacol 2002; 58(1): 81-2
27. Aronson JK. *The Blood Doctor*. [Barbara Vine; Viking, 2002]. BMJ 2002; 325(7375): 1307. [PMCID: PMC1124773]
28. Aronson JK. *Dying for Drugs* [Channel 4, 27 April 2003]. BMJ 2003; 326(7396): 990. [PMCID: PMC1125906]
29. Aronson JK. *One Man's Medicine* [BBC Radio 4, 6-20 August, 2003]. BMJ 2003; 327(7413): 507. [PMCID: PMC188412]
30. Aronson JK. *The \$800 Million Pill: The Truth Behind the Cost of New Drugs* [Merrill Goozner; University of California Press, 2004]. BMJ 2004; 329(7465): 577. [PMCID: PMC516126]

15. It's all Gweek to me. 17 May 2015. <http://blogs.bmj.com/bmj/2015/05/15/jeffrey-aronson-when-i-use-a-word-its-all-gweek-to-me>
16. The X factor. 22 May 2015. <http://blogs.bmj.com/bmj/2015/05/22/jeffrey-aronson-when-i-use-a-word-the-x-factor>
17. Join the Q. 29 May 2015. <http://blogs.bmj.com/bmj/2015/05/29/jeff-aronson-when-i-use-a-word-join-the-q>
18. Phonetic Alphabets. 5 June 2015. <http://blogs.bmj.com/bmj/2015/06/05/jeff-aronson-when-i-use-a-word-phonetic-alphabets>
19. Medical logos. 12 June 2015. <http://blogs.bmj.com/bmj/2015/06/12/jeffrey-aronson-when-i-use-a-word-medical-logos>
20. The Story of Ough. 19 June. <http://blogs.bmj.com/bmj/2015/06/19/jeffrey-aronson-when-i-use-a-word-the-story-of-ough>
21. An indefinite article. 26 June 2015. <http://blogs.bmj.com/bmj/2015/06/26/jeffrey-aronson-when-i-use-a-word-an-indefinite-article>
22. Breaking bad. 3 July 2015. <http://blogs.bmj.com/bmj/2015/07/03/jeffrey-aronson-when-i-use-a-word-breaking-bad>
23. Breaking worse. 10 July 2015. <http://blogs.bmj.com/bmj/2015/07/10/jeffrey-aronson-when-i-use-a-word-breaking-worse>
24. Breaking worst. 17 July 2015. <http://blogs.bmj.com/bmj/2015/07/17/jeffrey-aronson-when-i-use-a-word-breaking-worst>
25. Back breaking. 24 July 2015. <http://blogs.bmj.com/bmj/2015/07/24/jeffrey-aronson-when-i-use-a-word-back-breaking>
26. Back slang. 31 July 2015. <http://blogs.bmj.com/bmj/2015/07/31/jeffrey-aronson-when-i-use-a-word-backslang>
27. Get shorty. 7 August 2015. <http://blogs.bmj.com/bmj/2015/08/07/jeffrey-aronson-when-i-use-a-word-get-shorty>
28. Backronyms. 14 August 2015. <http://blogs.bmj.com/bmj/2015/08/14/jeffrey-aronson-when-i-use-a-word-backronyms>
29. Ars magna. 21 August 2015. <http://blogs.bmj.com/bmj/2015/08/21/jeffrey-aronson-when-i-use-a-word-ars-magna>
30. The first medical word. 28 August 2015. <http://blogs.bmj.com/bmj/2015/08/28/jeffrey-aronson-when-i-use-a-word-the-first-medical-word>
31. Medical onomatopoeia. 4 September 2015. <http://blogs.bmj.com/bmj/2015/09/04/jeffrey-aronson-when-i-use-a-word-medical-onomatopoeia>
32. Gargantuan gargoyles. 11 September 2015. <http://blogs.bmj.com/bmj/2015/09/11/jeffrey-aronson-when-i-use-a-word-gargantuan-gargoyles>
33. Adam's throat-bowl. 18 September 2015. <http://blogs.bmj.com/bmj/2015/09/18/jeffrey-aronson-when-i-use-a-word-adams-throat-bowl>
34. Adam's apple. 25 September 2015. <http://blogs.bmj.com/bmj/2015/09/25/jeffrey-aronson-when-i-use-a-word-adams-apple>
35. Adam's navel. 2 October 2015. <http://blogs.bmj.com/bmj/2015/10/02/jeffrey-aronson-when-i-use-a-word-adams-navel>
36. Black fire, spiders, and dogs. 9 October 2015. <http://blogs.bmj.com/bmj/2015/10/09/jeffrey-aronson-when-i-use-a-word-black-fire-spiders-and-dogs>
37. Red fire. 16 October 2015. <http://blogs.bmj.com/bmj/2015/10/16/jeffrey-aronson-when-i-use-a-word-red-fire>
38. All gall. 23 October 2015. <http://blogs.bmj.com/bmj/2015/10/23/jeffrey-aronson-when-i-use-a-word-all-gall>
39. A twist on the Nobel Prize. 30 October 2015. <http://blogs.bmj.com/bmj/2015/10/30/jeffrey-aronson-when-i-use-a-word-a-twist-on-the-nobel-prize>
40. A full bladder. 6 November 2015. <http://blogs.bmj.com/bmj/2015/11/06/jeffrey-aronson-when-i-use-a-word-a-full-bladder>
41. Let's twist again. 13 November 2015. <http://blogs.bmj.com/bmj/2015/11/13/jeffrey-aronson-when-i-use-a-word-lets-twist-again>
42. Terrorism. 20 November 2015. <http://blogs.bmj.com/bmj/2015/11/20/jeffrey-aronson-when-i-use-a-word-terrorism>
43. Conciliatory. 27 November 2015. <http://blogs.bmj.com/bmj/2015/11/27/jeffrey-aronson-when-i-use-a-word-conciliatory>

44. Keep on twisting. 4 December 2015. <http://blogs.bmj.com/bmj/2015/12/04/jeffrey-aronson-when-i-use-a-word-keep-on-twisting>
45. Fabian-tactics. 11 December 2015. <http://blogs.bmj.com/bmj/2015/12/11/jeffrey-aronson-when-i-use-a-word-fabian-tactics>
46. Magazines. 18 December 2015. <http://blogs.bmj.com/bmj/2015/12/18/jeffrey-aronson-when-i-use-a-word-magazines>
47. Medical anniversaries in 2016. 1 January 2016. <http://blogs.bmj.com/bmj/2016/01/01/jeffrey-aronson-when-i-use-a-word-medical-anniversaries-in-2016>
48. Quacks, mountebanks, and charlatans. 8 January 2016. <http://blogs.bmj.com/bmj/2016/01/08/jeffrey-aronson-when-i-use-a-word-quacks-mountebanks-and-charlatans>
49. Striking tactics. 15 January 2016. <http://blogs.bmj.com/bmj/2016/01/15/jeffrey-aronson-when-i-use-a-word-striking-tactics>
50. Fifty up. 22 January 2016. <http://blogs.bmj.com/bmj/2016/01/22/jeffrey-aronson-when-i-use-a-word-fifty-up>
51. Apothecaries. 29 January 2016. <http://blogs.bmj.com/bmj/2016/01/29/jeffrey-aronson-when-i-use-a-word-apothecaries>
52. Contemptuous. 5 February 2016. <http://blogs.bmj.com/bmj/2016/02/05/jeffrey-aronson-when-i-use-a-word-contemptuous>
53. A penicillin anniversary. 12 February 2016. <http://blogs.bmj.com/bmj/2016/02/12/jeffrey-aronson-when-i-use-a-word-a-penicillin-anniversary>
54. Pro patria mori. 19 February 2016. <http://blogs.bmj.com/bmj/2016/02/19/jeffrey-aronson-when-i-use-a-word-pro-patria-mori>
55. Imposition. 26 February 2016. <http://blogs.bmj.com/bmj/2016/02/26/jeffrey-aronson-when-i-use-a-word-imposition>
56. Andrew Herxheimer and his Golden Rules of drug therapy. 4 March 2016. <http://blogs.bmj.com/bmj/2016/03/04/when-i-use-a-word-andrew-herxheimer-and-his-golden-rules-of-drug-therapy>
57. Value and fulfilment. 11 March 2016. <http://blogs.bmj.com/bmj/2016/03/11/jeffrey-aronson-when-i-use-a-word-value-and-fulfilment>
58. Naming biologics—rINNs and pINNs. 18 March 2016. <http://blogs.bmj.com/bmj/2016/03/18/jeffrey-aronson-when-i-use-a-word-naming-biologics>
59. Naming biologics—principles and practice. 25 March 2016. <http://blogs.bmj.com/bmj/2016/03/25/jeffrey-aronson-when-i-use-a-word-naming-biologics-principles-and-practice>
60. Naming biologics—biosimilars. 1 April 2016. <http://blogs.bmj.com/bmj/2016/04/01/jeffrey-aronson-when-i-use-a-word-naming-biologics-biosimilars>
61. Mechanisms. 8 April 2016. <http://blogs.bmj.com/bmj/2016/04/08/jeffrey-aronson-when-i-use-a-word-mechanisms>
62. Mechanisms and evidence. 15 April 2016. <http://blogs.bmj.com/bmj/2016/04/15/jeffrey-aronson-when-i-use-a-word-mechanisms-and-evidence>
63. A contract or a contra-act? 22 April 2016. <http://blogs.bmj.com/bmj/2016/04/22/jeffrey-aronson-when-i-use-a-word-a-contract-or-a-contra-act>
64. Weasel words. 29 April 2016. <http://blogs.bmj.com/bmj/2016/04/29/jeffrey-aronson-when-i-use-a-word-weasel-words>
65. Recognising weasel words. 6 May 2016. <http://blogs.bmj.com/bmj/2016/05/06/jeffrey-aronson-when-i-use-a-word-recognising-weasel-words>
66. Mandates and manifestos. 13 May 2016. <http://blogs.bmj.com/bmj/2016/05/13/jeffrey-aronson-mandates-and-manifestos>
67. Political personification. 20 May 2016. <http://blogs.bmj.com/bmj/2016/05/20/jeffrey-aronson-when-i-use-a-word-political-personification>
68. Errors. 27 May 2016. <http://blogs.bmj.com/bmj/2016/05/27/jeffrey-aronson-when-i-use-a-word-errors>
69. MARKing and preventing medication errors. 3 June 2016. <http://blogs.bmj.com/bmj/2016/06/03/jeffrey-aronson-when-i-use-a-word-marking-and-preventing-medication-errors>
70. Tariffs. 10 June 2016. <http://blogs.bmj.com/bmj/2016/06/10/jeffrey-aronson-when-i-use-a-word-tariffs>
71. Delamothe. 17 June 2016. <http://blogs.bmj.com/bmj/2016/06/17/jeffrey-aronson-when-i-use-a-word-delamothe>

72. Leave or remain. 20 June 2016. <http://blogs.bmj.com/bmj/2016/06/20/jeffrey-aronson-when-i-use-a-word-leave-or-remain>
73. Medical patronymics. 23 June 2016. <http://blogs.bmj.com/bmj/2016/06/24/jeffrey-aronson-when-i-use-a-word-medical-patronymics>
74. More medical patronymics. 1 July 2016. <http://blogs.bmj.com/bmj/2016/07/01/jeffrey-aronson-when-i-use-a-word-more-medical-patronymics>
75. A memorandum about referendums. 8 July. <http://blogs.bmj.com/bmj/2016/07/08/jeffrey-aronson-when-i-use-a-word-a-memorandum-about-referendums>
76. Re: -er or -re. 15 July 2016. <http://blogs.bmj.com/bmj/2016/07/15/jeffrey-aronson-when-i-use-a-word-re-er-or-re>
77. A ban to abandon. 22 July 2016. <http://blogs.bmj.com/bmj/2016/07/22/jeffrey-aronson-when-i-use-a-word-a-ban-to-abandon>
78. Nutraceuticals and functional foods. 29 July 2016. <http://blogs.bmj.com/bmj/2016/07/29/jeffrey-aronson-when-i-use-a-word-nutraceuticals-and-functional-foods>
79. "The pharmaceutical industry"—the definite article. 5 August 2016. <http://blogs.bmj.com/bmj/2016/08/05/when-i-use-a-word-the-pharmaceutical-industry-the-definite-article>
80. Narcissism. 12 August 2016. <http://blogs.bmj.com/bmj/2016/08/12/jeffrey-aronson-when-i-use-a-word-narcissism>
81. Cupping. 19 August 2016. <http://blogs.bmj.com/bmj/2016/08/19/jeff-aronson-when-i-use-a-word-cupping>
82. Junior. 26 August 2016. <http://blogs.bmj.com/bmj/2016/08/26/jeff-aronson-when-i-use-a-word-junior>
83. Humours and humour. 2 September 2016. <http://blogs.bmj.com/bmj/2016/09/02/jeffrey-aronson-when-i-use-a-word-humours-and-humour/>

J2. CEBM blogs

(a) When I Use an Evidence Based Word

1. Blogs and logs. <http://www.cebm.net/when-i-use-an-evidence-based-word-1>
2. The roots of language. <http://www.cebm.net/use-evidence-based-word>
3. From roots to words. CEBMJ <http://www.cebm.net/use-evidence-based-word-3/> doi: 10.13140/RG.2.1.4716.5842
4. From phonemes to roots. <http://www.cebm.net/use-evidence-based-word-4>

(b) The Laws of Life

1. The Laws of Life: Theory and Evidence. <http://www.cebm.net/the-laws-of-life-theory-and-evidence>
2. The Laws of Life: Guldberg and Waage's Law of Mass Action. <http://www.cebm.net/the-laws-of-life-guldberg-and-waages-law-of-mass-action>
3. The Laws of Life: The Henderson-Hasselbalch equation and control of pH. In preparation

(c) The Hitchhiker's Guide to Clinical Pharmacology

1. Aronson J. Pharmacodynamics: How Drugs Work. 2016. doi: 10.13140/RG.2.1.4857.9446. <http://www.cebm.net/hitchhikers-guide-clinical-pharmacology>
2. Aronson J. How Drugs are Discovered and Developed. 2016. <http://www.cebm.net/hitchhikers-guide-clinical-pharmacology-2>

(d) Miscellaneous blogs

1. Happy fiftieth birthday, Yellow Cards. 9 December 2014. <http://www.cebm.net/happy-fiftieth-birthday-yellow-cards>
2. Everyone should read "Being Mortal". 5 January 2015. <http://www.cebm.net/opportunity-costs>
3. A standard national UK hospital prescription chart. 27 January 2015. <http://www.cebm.net/standard-national-uk-hospital-prescription-chart>
4. Why do we need new formulations of old drugs for new indications? 20 February 2015. <http://www.cebm.net/old-drugs-new-indications>
5. A VOICE for medical specialties – a paradigm to be heard. 23 April 2015. <http://www.cebm.net/a-voice-for-medical-specialties>

6. Perepilichny and Gelsemium. 3 June 2015. <http://www.cebm.net/perepilichny>
7. Scientific Research—Thirteen Principles of Faith. 12 June 2015. <http://www.cebm.net/scientific-research-thirteen-principles-of-faith>
8. Big Pharma and Big Medicine: An Agenda for Collaboration. <http://www.cebm.net/big-pharma-big-medicine-agenda-collaboration>
9. Defining collaborative care as an alternative model to patient-centred care. <http://www.cebm.net/defining-collaborative-care-alternative-model-patient-centred-care>

J3. Other blogs

1. 6/60 Vision: Celebrating the BNF and BNFC. 24 October 2010. <http://blogs.bmj.com/bmj/2010/11/24/jeffrey-aronson-660-vision-celebrating-the-bnf-and-bnfc>
2. Happy 50th birthday, Yellow Cards. BMJ 8 December 2014. <http://blogs.bmj.com/bmj/2014/12/08/jeffrey-aronson-happy-50th-birthday-yellow-cards>
3. [Onakpoya I, Heneghan C, Aronson J.] Withdrawal of medicines that cause deaths: takes longer than you think. 5 February 2015. <http://blogs.biomedcentral.com/on-medicine/2015/02/05/withdrawal-medicines-cause-deaths-takes-longer-think>